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ABSTRACT 
Nine acyl-CoA dehydrogenases (ACADs) are involved in mitochondrial fatty acid β-oxidation 
(FAO), an important energy-producing pathway. Disorders of FAO are common inborn errors of 
metabolism and genetic deficiencies have been identified for all ACADs except long-chain acyl-
CoA dehydrogenase (LCAD).  Understanding the function of LCAD and the phenotype of 
LCAD deficiency may enable identification of unrecognized cases of LCAD deficiency, and 
eventual treatment, and improve public health. 
I hypothesized that human LCAD (hLCAD) and mouse LCAD (mLCAD) are 
biochemically equivalent, but that hLCAD functions in tissues not normally reliant upon FAO, 
such as the lung.  Additionally, I hypothesized that a missense polymorphism (K333Q), linked to 
an absence of LCAD antigen in human lung, is deleterious. Recombinant mLCAD, hLCAD, and 
hLCAD K333Q proteins were purified and biochemically characterized.  Recombinant mLCAD 
was more stable and demonstrated higher catalytic efficiency than hLCAD.  Additionally, 
recombinant hLCAD bearing the K333Q substitution demonstrated lower activity, impaired 
substrate binding, and reduced stability compared to wild-type hLCAD.  
Based on these findings and on western blotting experiments demonstrating higher 
LCAD expression in human lung than other long-chain ACAD enzymes, I hypothesized that 
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LCAD K333Q may be associated with lung disease. Primary alveolar type II (ATII) cells from 
individuals homozygous for the minor Q allele had five-fold less LCAD antigen than ATII cells 
from individuals homozygous for the major K allele, consistent with lower protein stability. 
Cohorts of neonates with respiratory distress syndrome and children hospitalized for pneumonia 
were genotyped for LCAD K333Q.  Association of lung function with different genotypes at the 
K333Q locus was examined in the Long Life Family Study (LLFS) (N=4953).  Contrary to the 
hypothesis, the LCAD K333Q locus was not associated with lung disease.  Heterozygotes for the 
Q allele were under-represented among children hospitalized with pneumonia, whereas 
homozygotes for the K allele were over-represented, suggesting that carrier status for K333Q 
confers some benefit.  Individuals in the LLFS who carried the Q-allele at the K333Q locus had 
increased lung function.  In conclusion, recombinant mLCAD was biochemically superior to 
hLCAD, which was superior to hLCAD K333Q.  However, the K333Q polymorphism was not 
associated with respiratory distress or pneuomonia-induced complications. 
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1.0  INTRODUCTION 
1.1 FATTY ACID OXIDATION 
Fatty acid oxidation (FAO) is the sequential cleavage of free acetyl-CoA groups from long-chain 
fatty acids to provide an important source of energy to support muscle activity, non-shivering 
thermogenesis, and liver function, particularly during illness, stress, and fasting (Vockley J. and 
Whiteman D.A.H 2002).  Fatty acids are an important source of energy within tissues that 
require high amounts of energy:  heart, brown adipose tissue, skeletal muscle, and liver 
(Goetzman E.S., 2011).  Twenty-five proteins responsible for transport and enzymes are 
involved in FAO in the mitochondria.  Defects in 88% of these proteins have been reported to 
cause disease (Vockley J. and Whiteman D.A.H. 2002).  FAO begins with the conversion of fatty 
acyl-CoA substrates to acylcarnitines by the enzyme carnitine palmitoyltransferase-I (CPT1), a 
highly-regulated enzyme that serves as the “gatekeeper” for mitochondrial FAO.  Acylcarnitines 
are transported through the outer and inner mitochondrial membranes and then converted back 
into acyl-CoAs in the mitochondrial matrix by carnitine palmitoyltransferase-2 (CPT2). The 
carnitine shuttle has great clinical relevance in FAO disorders. In the face of accumulating acyl-
CoAs, which tie up the intra-mitochondrial CoA pool, CPT2 can catalyze the reverse reaction, 
resulting in efflux of acylcarnitines from the mitochondria. These acylcarnitines then accumulate 
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in blood where they are diagnostic for FAO disorders, and are the basis of newborn screening 
programs for these diseases (Moczulski D., et al. 2009). 
Once inside the matrix, long-chain acyl-CoAs are processed through four steps of β-
oxidation in which an acetyl-CoA is produced through the cleaving of two carbons from the fatty 
acid.  These four steps include dehydrogenation, hydration, another dehydrogenation, and finally 
a thiolytic cleavage (Moczulski D., et al. 2009).  The first step of dehydrogenation is the creation 
of a trans-α,β double bond through the action of acyl-CoA dehydrogenase enzymes (Chegary M., 
et al. 2009), with concomitant transfer of electrons to electron transfer flavoprotein (ETF) 
(Roberts D.L., et al. 1996).  ETF Dehydrogenase oxidizes the reduced ETF, the electrons are 
then passed to coenzyme Q, and finally to complex III where it can go through the mitochondrial 
respiratory chain to produce ATP (Goetzman E.S., 2011) (Ruzicka F.J. and Beinert H. 1977).  
The second step of FAO is the hydration of 2-enoyl-CoA to 3-hydroxyacyl-CoA.  The third step 
is the creation of 2-ketoacyl-CoA through 2,3 dehydrogenation of 3-hydroxyacyl-CoA.  This 
dehydrogenation is reliant on NAD+ as a cofactor.  The fourth and final step is the production of 
acetyl-CoA and an acyl-CoA that has been shortened in length by two carbons through the 
cleaving of the thioester bond by a thiolase.  The shortened acyl-CoA can begin the cycle again 
at the first step of β-oxidation to cleave another acetyl-CoA.  
The FAO pathway functionally interacts with the TCA cycle and the electron transport 
chain at multiple points (Figure 1). First, each FAO cycle directly produces NADH and FADH2 
that are sent to the respiratory chain to be oxidized and produce ATP. Second, the acetyl-CoA 
produced by β-oxidation can be subsequently oxidized to completion by the TCA cycle, further 
producing NADH and FADH2 that is then sent to the mitochondrial respiratory chain (Moczulski 









Figure 1: Interaction of B-Oxidation, TCA Cycle, and Respiratory Chain 
1.2 ACYL-COA DEHYDROGENASE ENZYMES 
 Acyl-CoA dehydrogenase (ACAD) family members and substrate specificity. 
The first dehydrogenation step in FAO is executed by the family of ACAD enzymes.  There are 
9 confirmed ACAD enzymes (Swigoňová Z., et al. 2009).  Five of these enzymes play a role in 
FAO by catalyzing the production of trans-enoyl-CoA through the α,β-dehydrogenation of 
substrates:  short-chain acyl-CoA dehydrogenase (SCAD), medium-chain acyl-CoA 
dehydrogenase (MCAD), long-chain acyl-CoA dehydrogenase (LCAD), very long-chain acyl-
CoA dehydrogenase (VLCAD), and acyl-CoA dehydrogenase 9 (ACAD9).  As suggested by 
their names, these five enzymes have differing substrate specificities.  SCAD is active against 
short-chain acyl-CoAs 4 to 6 carbons in length, while MCAD oxidizes fatty acids of 6 to 16 
carbons in length (Finocchiaro G., et al. 1987). VLCAD is active against acyl-CoAs of 14 to 20 
carbons (Souri M., et al. 1998).  There are two isoforms of VLCAD, dubbed the long and short 
4 
forms, due to alternative splicing of exon 3 (Goetzman E.S., et al. 2007). ACAD9 oxidizes fatty 
acids of approximately 10 carbons to about 18 carbons, but has even greater activity toward 
unsaturated fatty acids with the highest activity toward cis-9-C16:1-CoA (He M., et al. 2007) 
(Zhang J., et al. 2002) (Ensenauer R., et al. 2005).  Finally, LCAD has broad substrate 
specificity, exhibiting overlap with MCAD, VLCAD, and ACAD9, in that it demonstrates 
activity against saturated and unsaturated acyl-CoAs from 8 to 18 carbons as well as branched-
chain acyl-CoAs (Le W., et al. 2000).   
Four ACAD enzymes play roles in amino acid catabolism:  isovaleryl-CoA 
dehydrogenase (IVD) has enzymatic activity toward leucine, short/branched-chain acyl-CoA 
dehydrogenase or additionally known as 2-methyl branched-chain acyl-CoA dehydrogenase 
(SBCAD) catabolizes isoleucine, isobutyryl-CoA dehydrogenase (IBD) catabolizes valine, and 
glutaryl-CoA dehydrogenase (GCD) catabolizes lysine and tryptophan (Swigoňová Z., et al. 
2009).  Two additional ACADs, acyl-CoA dehydrogenase 10 (ACAD10) and acyl-CoA 
dehydrogenase 11 (ACAD11), have been reported.  The specific enzymatic activity of those 
ACADs has yet to be confirmed.  However, the sequences of these proteins are homologous to 
the other ACADs (Swigoňová Z., et al. 2009).  The ACAD enzymes are encoded in the nucleus.  
The precursor proteins are synthesized in the cytosol, transported into the mitochondria, and 
finally processed through a proteolytic mechanism into mature forms (Swigoňová Z., et al. 2009) 
(Goetzman E.S., 2011).  All ACADs, as well as their redox partner ETF, are flavoproteins that 
incorporate a non-covalently bound flavin adenine dinucleotide (FAD) (Wanders R.J., et al. 
1999) (Goetzman E.S., 2011) (Swigoňová Z., et al. 2009) during protein folding inside the 
mitochondrial matrix (Goetzman E.S., 2011). 
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 Structure of ACAD Enzymes. 
SCAD, MCAD, IVD, IBD, SBCAD, GCD, and LCAD are homotetramers (Figure 2) (Toogood 
H.S., et al. 2006).  On the other hand, the ACADs VLCAD and ACAD9 are homodimers (Figure 
3) (Pike A.C.W., et al. 2007).  Additionally, SCAD, MCAD, IVD, IBD, SBCAD, GCD as well 
as LCAD are found in the mitochondrial matrix.  VLCAD and ACAD9 are bound to the 
mitochondrial membrane.  The crystal structures of human VLCAD, MCAD, IVD, and IBD 
have been reported.  The ACAD monomers consist of tertiary folds of an NH2-terminal domain 
of α-helices, a COOH-terminal domain of α-helices, as well as a central domain of β-sheets.  
LCAD has no reported crystal structure.  Each monomer contains a non-covalently bound FAD 
cofactor.  The flavin moiety of an FAD is bound at the active site of a subunit between the 
central β-sheet and the α-helices of the carboxyl terminus whereas the adenine moiety of the 
same FAD cofactor is bound between the α-helices of the carboxyl terminus of the adjacent 
subunit (Swigoňová Z., et al. 2009).  Each ACAD has a spectrum including a peak of absorbance 
near 280nm as well as a peak near 445nm (Mohsen A.-W. and Vockley J. 2015).  ETF is 
responsible for the transfer of electrons during the enzymatic activity of ACADs.  Crystal 
structure analysis of MCAD shows a complex of MCAD with ETF through about 10 arginine 
residues as well as six histidine residues (Parker A.R., 2003).  All ACADs have been shown to 
have a glutamic acid as the catalytic base responsible for initiating dehydrogenation of α-proton-
abstracting.  The location of the catalytic base is E376 in SCAD as well as MCAD.  However, 
the location of the catalytic base is not conserved in LCAD, but is instead E261 (Djordjevic S., et 
al. 1994).    
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Figure 3: Crystal Structure of a Homodimer of Human VLCAD (pdb 2UXW) 
 Human ACAD Enzyme Deficiencies and Public Health Significance 
FAO in the mitochondria provides maintenance of energy homeostasis during conditions of 
stress or fasting (Chegary M., et al. 2009).  Genetic diseases have been associated with the 
dysfunction of at least 22 of the 25 enzymes that are known to play a role in mitochondrial FAO 
(Vockley J. and Whiteman D.A.H. 2002). For the ACAD enzyme family, genetic deficiencies 
have been noted for eight out of the nine bona fide ACADs, with LCAD being the only 
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exception.  However, as a group, genetic disorders of FAO are the most common inborn errors of 
metabolism (Chegary M., et al. 2009).  Inborn errors of FAO are estimated to contribute to up to 
5% of sudden unexplained infant death (Moczulski D., et al. 2009).  Therefore, understanding as 
well as treating disorders of FAO is of great public health significance. 
 The most common disorder of FAO is Medium-Chain Acyl-CoA Dehydrogenase 
Deficiency (MCADD), which is seen in about 1 out of every 15,001 births (Andresen B.S., et al. 
2001).  The symptoms of this most common disorder of FAO begin in early childhood after 
decreased intake of dietary carbohydrates concurrent with illness or fasting.  The symptoms 
include vomiting, lethargy, hypotonia, possible mild hepatomegaly, seizures, hypoglycemia, 
hyperammonemia, and increased liver enzymes.  The symptoms range from early hypoglycemia 
in newborns to asymptomatic.  Prior to the development of successful newborn screening by 
tandem mass spectrometry to facilitate the diagnosis of MCADD, about 25% of the patients died 
due to their first episode (Wanders R.J., et al. 1999) (Wilcken B., et al. 1994).  Treatment of 
MCADD involves the rapid treatment of episodes with hydration, glucose given intravenously, 
L-carnitine may be given intravenously when it is not possible to give it enteral or if the episode 
is severe.  The current treatment to prevent episodes is the avoidance of fasting (Moczulski D., et 
al. 2009).   
 Another inborn error of FAO is SCAD deficiency.  The prevalence of SCADD is 
estimated to be approximately 1 out of 50,000 births.  The phenotype of SCAD deficiency 
(SCADD) manifests a variety of symptoms including metabolic acidosis, ketotic hypoglycemia, 
development, failure to thrive, developmental delay, seizures, and neuromuscular symptoms 
including myopathy and hypotonia.  The symptoms of SCADD typically decrease with age.  
Treatment of acute symptoms of SCADD includes intravenous high dextrose fluids as in other 
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disorders of FAO.  Symptoms of SCADD might be prevented by avoiding fasting (Jethva R., et 
al. 2008). 
 Patients with a deficiency of ACAD9 demonstrate a variable phenotype with 
cardiomyopathy, episodic liver dysfunction during mild illness with ingestion of aspirin, as well 
as chronic neurological dysfunction.  The substrate specificity of ACAD9 overlaps with 
VLCAD.  However, VLCAD does not appear capable of compensating for the loss of ACAD9 
(He M., et al. 2007).  This observation may be explained by the discovery that ACAD9 has a role 
in the assembly of Complex I of the mitochondrial respiratory chain in addition to FAO.  
Therefore, both the loss of long-chain FAO as well as the assembly of Complex I may contribute 
to the symptoms of ACAD9 deficiency (Schiff M., et al. 2015). 
Between 1985 and 1993, 13 patients were described with a long-chain FAO disorder that 
was ascribed to deficiency of LCAD.  These patients were reported with symptoms of 
cardiomegaly, hepatomegaly, hypoketotic hypoglycemia, as well as muscle weakness.    
However, with the discovery of the VLCAD gene in 1993, patients who were previously 
reported as having LCADD were instead deficient in VLCAD protein (Yamaguchi S., et al. 
1993).  VLCAD Deficiency (VLCADD) manifests in patients with early onset cardiomyopathy 
and skeletal myopathy as well as hypoketotic hypoglycemia, hyperammonemia, dysfunction of 
hepatocytes, cardiac arrhythmia, rhabdomyolysis, and myopathy in adolescence (Vockley J. and 
Whiteman D.A.H. 2002) (Aoyama T., et al. 1995).  The current treatment for VLCADD patients 
is the prevention of fasting, low fat diet, and supplementation of medium chain triglycerides 




 Reversible post-translational lysine acetylation as a regulator of ACAD enzymes. 
In addition to being the “powerhouse” of the cell, mitochondria are involved in multiple 
signaling pathways including apoptosis (Papanicolaou K.N., et al. 2014).  Therefore, the 
regulation of mitochondrial signaling pathways may have significant consequences to cellular 
function.  Lysine acetylation of mitochondrial proteins, as well as other post-translational 
modifications, impacts the signaling pathways of the mitochondria.  Complex changes of 
acetylation in the mitochondria have been correlated with altered substrate fluctuation during 
fasting and feeding (Papanicolaou K.N., et al. 2014).  Acetyl-CoA, the product of FAO, is the 
acetyl group donor for lysine acetylation of mitochondrial proteins, including the ACADs and 
other members of the FAO enzymatic machinery (Papanicolaou K.N., et al. 2014). The 
acetylation of lysines can be reversed in an NAD+-dependent manner by the sirtuin (Sirt) family 
of lysine deacylase enzymes.  Reversible lysine acetylation may play a role in the 
pathophysiology of FAO disorders.  Importantly, our lab has previously shown that acetylation 
of two lysines in recombinant mouse LCAD, K318 and K322, reduces the enzymatic activity 
(Bharathi S.S., et al. 2013).  Similarly, acetylation/succinylation of key lysine residues on 
VLCAD inhibits enzymatic activity and membrane localization (Zhang Y., et al. 2015). Removal 
of the acetyl groups by Sirt3 rescues the loss of the enzymatic activity (Bharathi S.S., et al. 
2013).  Interestingly, aspirin, which can trigger Reye-like symptoms and acute symptoms in 
patients with FAO disorders (Tein I., 2015) (He M., et al. 2007), has been shown to acetylate 
multiple cellular proteins (Wang J., et al. 2015). This process appears to occur via transfer of the 
acetyl group of acetylsalicylic acid (aspirin) directly to protein lysines (Wang J., et al. 2015). 
Thus, protein acetylation may contribute to aspirin-induced metabolic decompensation among 
patients with mutations in the FAO pathway. 
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1.3 LCAD:  THE “ORPHAN” ACAD ENZYME 
 LCAD deficiency may present differently than other ACAD deficiencies 
As detailed above, genetic diseases are associated with all ACAD enzymes except LCAD 
(Vockley J. and Whiteman D.A.H. 2002).  There are three plausible explanations for the absence 
of patients with disease-causing mutations in LCAD.  The first possible explanation is that 
LCADD is embryonic lethal.  No live patients would then be found.  Evidence to support this 
possibility comes from the LCAD knockout mouse model, which has reduced litter size due to 
early embryonic lethality (Berger P.S. and Wood P.A. 2004) (Kurtz D.M., et al. 1998).  A second 
plausible explanation is that the phenotype of LCADD differs from known acyl-CoA 
dehydrogenase (ACAD) deficiencies, so the disease has not been recognized as an ACAD 
deficiency.  For example, Roberts and colleagues suggested that LCAD deficiency may be 
associated with the development of autism (Roberts J.L., et al. 2014).  Additionally, LCAD is the 
only long-chain ACAD that is appreciably expressed in the human lung, kidney, thyroid gland, 
and prostate (He M., et al. 2007).  Our lab has demonstrated a role for LCAD in the production 
of surfactant in the lung, and identified cases of SIDS where no LCAD antigen was visible in 
lung tissue.  LCAD knockout mice displayed altered lipid composition and function of 
pulmonary surfactant (Goetzman E.S., et al. 2014). This result indicates that a possible LCADD 
patient may present with symptoms very unlike those of a traditional long-chain FAO disorder 
such as VLCADD, which affects the heart, muscle, and liver (He M., et al. 2007). A final 
possible explanation may be that a loss of LCAD does not result in any phenotype, so there is no 
disease of LCADD.  The central hypothesis of my thesis, which will be detailed in a subsequent 
11 
section, is that LCADD patients exist, but they manifest a different clinical picture than other 
ACAD deficiencies. 
 Lessons from the LCAD knockout mouse model. 
An LCAD knockout mouse model was created in the laboratory of Dr. Philip Wood nearly 20 
years ago. The phenotype of the LCAD knockout mouse consists of intolerance of cold and 
fasting, hypoketotic hypoglycaemia, fatty acid changes in liver and heart tissue, and even sudden 
death.  This phenotype is strikingly similar to human VLCAD deficiency (Kurtz D.M., et al. 
1998) (Van Viles N., et al. 2005). LCAD-/- mice also accumulate C14:1-acylcarnitine, the 
hallmark biochemical marker for human VLCAD deficiciency, in blood and multiple tissues 
(Kurtz D.M., et al. 1998) (Cox K.B., et al. 2001) 
LCAD has also been suggested to play a role in fat tissues.  The hypothalamic-
sympathetic network works in conjunction with brown adipose tissue and has a significant 
function in energy metabolism (Motyl K.J., et al. 2013).  Misty mice have reduced brown adipose 
tissue function (Motyl K.J., et al. 2013).  Misty mice have reduced baseline levels of LCAD, 
however, during exposure to cold Misty mice had elevated expression of genes, including LCAD, 
that are correlated with white adipose tissue transitioning toward brown adipose tissue (Motyl 
K.J., et al. 2013).  In mice, a morphological alteration from white adipose cells to cells that 
resemble brown adipocytes with higher number of mitochondria has been reported to occur with 
an increased metabolic rate in white adipose tissues.  Therefore, LCAD may play a role in 
regulating the transition of white fat to brown fat in order to provide the needed metabolism as 
well as heat energy.  This could also be confirmed in the cold-intolerance of LCAD -/- mice 
(Guerra C., et al. 1998). 
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 Why mitochondria possess both LCAD and VLCAD is not clear, because they have 
largely overlapping substrate specificities.  In mice, LCAD is widely expressed and appears to 
play a dominant role over VLCAD in the FAO pathway. This conclusion is evidenced by a 
comparison of the LCAD and VLCAD knockout mouse models. Compared to either LCAD 
knockout mice or humans with VLCADD, the VLCAD knockout mouse model (VLCAD -/-) 
manifests a phenotype that is much more mild.  Enzyme activity assays with LCAD-/- and 
VLCAD-/- liver homogenates indicated a more severe loss of total long-chain ACAD activity in 
the LCAD-/- strain. As a result, VLCAD -/- mice show only mild hepatic steatosis and mild fatty 
acid change in the heart, and only under the stress of extreme fasting or cold temperatures (Cox 
K.B., et al. 2001). In contrast, LCAD-/- mice develop much more severe hepatic steatosis and 
signs of cardiac involvement (Cox K.B., et al. 2001). Therefore, our understanding of the 
physiology of the mouse models of LCAD -/- and VLCAD -/- and their representation of the 
human diseases is incomplete. 
 LCAD Single Nucleotide Polymorphism, K333Q 
The overall population frequency of a specific single nucleotide polymorphism (SNP) in LCAD 
(rs2286963) (LCAD K333Q) is estimated to range from 21.1% (1000 Genomes Project), to 
30.1% in the Exome Aggregation Consortium (ExAC) (Lek M, et al., 2015), to 27.7% NHLBI 
Grand Opportunity Exome Sequencing Project (GO-ESP) (Exome Variant Server, 2016) (NCBI. 
dbSNP Short Genetic Variations, 2013).  The minor allele frequency in specific populations 
ranges from 0.0471 in the Mende population in Sierra Leone to 0.3485 in Utah Residents (NCBI. 
1000 Genomes Browser, 2013).  The SNP LCAD K333Q is a missense mutation that changes a 
lysine to a glutamine (NCBI. dbSNP Short Genetic Variations, 2013), but it has not been 
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associated with a disease and is of unknown significance (NCBI. dbSNP Short Genetic 
Variations, 2013).  However, the metabolite C9-carnitine is elevated in the blood of those with 
the LCAD K333Q (Illig T., et al. 2010).  This metabolite is likely 2,6-dimethylheptanoyl-
carnitine, which is one of the branched-chain acyl-carnitine species that is predicted to 
accumulate with the dysfunction of LCAD (Van Viles N., et al. 2005).  Additionally, our lab 
found that two samples from infants who died from Sudden Unexplained Infant Death (SUID) 
that showed a lack of LCAD antigen by Western Blot analysis were homozygous for LCAD 
K333Q.  A sample from a third infant who also died from SUID exhibited LCAD antigen and 
was heterozygous for LCAD K333Q (Goetzman E.S., et al. 2014). 
LCAD K333Q was associated in a Geographic-wide Associated Study (GWAS) of the 52 
populations within the Human Genome Diversity Project with UV radiation (Pearson R value of 
0.813366; Hsu I., et al. 2013).  The SNP was also associated with an increased waist 
circumference.  However, when corrected for multiple testing with Bonferroni adjustments, the 
association was not significant (Banasik K., et al. 2011).  LCAD K333Q is associated with an 
increase of the mRNA of ACADL in liver tissue, but again, this relationship was not significant 
(P < 0.1) (Mirkov S., et al. 2012).  Additionally, no difference was found in LCAD antigen levels 
in the fibroblasts of Danish people who were homozygous wildtype, heterozygous, or 
homozygous for the polymorphism (Andresen B.S., et al. 1999). 
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1.4 HYPOTHESES AND SPECIFIC AIMS OF THIS STUDY 
 Human LCAD and mouse LCAD are functionally equivalent. 
I hypothesized that human LCAD (hLCAD) and mouse LCAD (mLCAD) are functionally 
equivalent.  This hypothesis was tested by comparing recombinant hLCAD to mLCAD in terms 
of a) substrate specificity, determined by measuring maximum activity of the recombinant 
enzymes across several different chain-length substrates; b) substrate binding, using an anaerobic 
substrate titration assay; c) stability; and d) catalytic efficiency, calculated from kinetic 
parameters obtained by enzyme activity assays.  Further, the tissue expression of mLCAD and 
hLCAD were examined using western blot of human breast, kidney, liver, lung, pancreas, 
prostate, and thyroid tissue lysates and mouse kidney, liver, lung, and pancreas tissue lysates 
with LCAD antibodies.  VLCAD, which has overlapping substrate specificity with LCAD, was 
also quantified (Souri M., et al. 1998) (Le W., et al. 2000).   
 The function of LCAD is regulated by post-translational modification. 
Our lab has previously shown that acetylation of mLCAD at lysines 318 and 322 reduces the 
enzymatic activity (Bharathi S.S., et al. 2013), and that this can be reversed by the sirtuin 
deacylase enzyme SIRT3.  Also, aspirin has recently been shown to acetylate cellular proteins, 
and historically aspirin has been recognized as a trigger of metabolic decompensation in patients 
with FAO disorders (Wang J., et al. 2015) (Tein I., 2015) (He M., et al. 2007). I hypothesized 
that aspirin may acetylate LCAD and reduced function. A human cell line was treated with 
aspirin and the resulting changes in hLCAD acetylation were measured. Finally, I examined 
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“global’ protein lysine acetylation in primary human primary alveolar type II (ATII) cells, which 
have not previously been characterized for this post-translational modification, because our 
laboratory has previously identified the ATII cells as a site of high hLCAD expression 
(Goetzman E.S., et al. 2014).   
 The common polymorphism of LCAD K333Q has detrimental consequences, 
particularly in the lung. 
As mentioned above, our laboratory has previously shown that lung ATII cells express high 
levels of hLCAD, and two cases of sudden infant death were identified with no LCAD antigen. 
Both were homozygous for missense polymorphism K333Q (Goetzman E.S., et al. 2014).  Based 
on this observation, I hypothesized that LCAD K333Q is a detrimental amino acid substitution 
that would serve as a risk factor for lung disease.  Recombinant hLCAD with the SNP K333Q in 
the sequence produces purified LCAD with wild type lysine changed to a glutamine in all 
monomers (hLCAD K333Q).  I assessed the impact of the SNP K333Q on recombinant hLCAD 
function toward five different acyl-CoA substrates as well as kinetic parameters and catalytic 
efficiency.  A substrate titration assay was also used to compare the abilities of recombinant 
hLCAD Wt and hLCAD K333Q to bind substrate.  Then, I examined a possible association of 
LCAD K333Q with human lung disease, using cohorts of children with respiratory distress 
syndrome or hospitalized for pneumonia.  Finally, I explored relationships between K333Q and 
measures of lung function in the Long Life Family Study (LLFS) database.   
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 LCAD has a role in the immune system, particularly in the lung. 
I also hypothesized that LCAD has a role in the immune system, particularly in the lung.  Some 
data shows that the SNP K333Q appears to be beneficial.  Therefore, it is suspected that a role of 
LCAD may be detrimental, and the reduction of the detrimental role through the SNP K333Q 
may be beneficial.  I examine this hypothesis because ATII cells where LCAD is expressed are 
involved in the immune system in the lung.  Additionally, the surfactant of LCAD -/- mice is 
abnormal and decreased in abundance, the lung function of LCAD -/- mice is reduced, and 
inflammation of LCAD -/- mice infected with influenza is significantly less than that of wild 
type mice.  Therefore, data is obtained from the LLFS in measures of possible association of the 
SNP K333Q with aspects of the immune system:  IL-6, white blood cell counts, and C-reactive 
protein.  Additionally, surfactant protein-A (SP-A) is examined by western blot in lung tissue 
lysates as well as bronchial alveolar lavage fluid of LCAD -/- mice compared to wild type mice 
to examine the secretion of SP-A into the surfactant.  SP-A is examined because it is expressed 
in ATII cells where LCAD is expressed and it has a role in the immune system. 
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2.0  MATERIALS AND METHODS 
2.1 PURIFICATION OF RECOMBINANT LCAD ENZYMES AND NATIVE ETF 
The aims of biochemically comparing mLCAD to hLCAD, and subsequently hLCAD to hLCAD 
K333Q, required purified recombinant LCAD proteins as well as purified native ETF to serve as 
the electron acceptor in enzyme activity assays. These protein reagents were prepared as 
described below. 
 Expression and purification of recombinant LCAD proteins. 
An E coli expression system for His-tagged mLCAD was previously described by our laboratory 
(Bharathi S.S., et al. 2013). For hLCAD, the hLCAD K333Q cDNA was obtained from Dr. Jung-
Ja Kim of the Medical College of Wisconsin and was inserted into the pTrcHis bacterial 
expression vector (Thermo Fisher Scientific) containing a C-terminal His-tag sequence.  
Bacterial expression of hLCAD K333Q produces monomers that all contain the change of a 
lysine to a glutamine at site 333.  Site-directed mutagenesis was then used to convert the hLCAD 
K333Q construct to wild type hLCAD using the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent Technologies).  To verify the reversion to the wild type sequence, plasmid DNA was 
prepared from four colonies using the GenElute Plasmid Miniprep Kit (Sigma-Aldrich) and 
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examined by restriction enzyme digest using the restriction enzyme BamHI to release the 





Figure 4:  1% Agarose Gel of BamHI Enzyme Digest of 4 Colonies from Q333K Mutagenesis 
 
Samples 2, 3, and 4 appeared to be the correct size and were sent to GeneWiz 










Figure 5:  Sequence of Lysine 333 to Confirm Single Site Mutation of SNP Q to Wild Type K 
 
All three recombinant LCAD proteins were expressed and purified in the same manner. 
Briefly, four-liter cultures of E. coli were induced overnight with 0.5 mM IPTG at 30 °C.  The E 
coli cultures were pelleted and lysed by sonication (Fisher Scientific Sonic Dismembrator 550) 
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on ice in a cooling cell.  Lysates were clarified by ultracentrifugation and the supernatants were 
applied to a 1 mL HisTrap column using an Amersham Pharmacia Biotech ÄKTA fast protein 
liquid chromatography (FPLC) system.  Bound proteins were eluted with 50 mM NaPO4, 100 
mM NaCl, 10% glycerol, 300 mM Imidizole, pH8 with a linear gradient over 30 column 
volumes.  Fractions containing LCAD were collected and dialyzed against 50mM NaPO4 pH 8, 
50mM NaCl, 10% glycerol, 0.2 mM DTT, and then concentrated to greater than 3 mg/mL prior 
to flash-freezing in liquid nitrogen and subsequent storage at -80C. The purity of each protein 
preparation was examined by resolving 1 µg of protein on an SDS-page gel (Bio-Rad TGX) and 








Figure 6:  Coomassie Stain of 1 µg of Recombinant hLCAD Wt, hLCAD K333Q, and mLCAD on SDS Page 
Gel 
 
The integrity of the purified hLCAD Wt and hLCAD K333Q proteins were determined 
by absorbance scanning and calculating the FAD ratio, defined as the ratio of total protein 
absorbance (A280) to the FAD absorbance (A445).  LCAD is a homotetramer with an FAD 
cofactor non-covalently bound to each monomer; increased FAD ratios above 9 indicate partial 
loss of FAD from the tetramer. For all experiments involving, the proteins were purified in the 
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same manner as described above except when mentioned that 100 uM FAD was added to the 
dialysis and storage buffer. Before use, the excess unbound FAD was removed from the storage 
buffer using size exclusion columns (Bio-Rad Micro Bio-Spin ™ P-30) by exchanging the 
column buffer for dialysis buffer and using the columns according to manufacturer instructions. 
 Purification of native porcine ETF. 
All ACAD enzymes use electron transferring flavoprotein (ETF), another flavoprotein, as their 
natural electron acceptor.  For biochemical characterization of the three LCAD recombinant 
proteins, purified native porcine ETF protein was used as the electron acceptor in activity assays 
and kinetics experiments.  Porcine ETF is used due to its high degree of intrinsic FAD-associated 
fluorescence, which becomes quenched as it accepts electrons from ACAD enzymes. To purify 
pig ETF, mitochondria were first isolated from freshly harvested pig liver.  Briefly, pig liver was 
homogenized in 50 mM KPO4, 1 mM EDTA, 2.5% glycerol, 250 mM sucrose, and the 
homogenate filtered through cheesecloth. The mitochondria were collected from the homogenate 
by a conventional differential centrifugation protocol, and mitochondrial pellets stored at -80 °C 
until time of ETF protein purification. 
To purify ETF protein, approximately 500 g of frozen mitochondria were sonicated in an 
equal volume of 320 mM KPO4, 10mM EDTA, 0.1 mg/mL FAD, and 0.2 mg/mL AMP 
(sonication buffer).  The lysate was ultracentrifuged and the supernatant subjected to ammonium 
sulfate precipitation by adding powdered ammonium sulfate to 45% saturation.  The sample was 
left to stir on ice for 10 minutes, then ultracentrifuged at 52,000 rpm for 35 minutes at 4 °C.  The 
supernatant was collected, stirred on ice, and brought to 60% ammonium sulfate saturation.  The 
ultracentrifuge step was repeated, and supernatant discarded.  The pellet was resuspended in 
21 
sonication buffer, transferred to a dialysis bag, and dialyzed against 5 liters of 15 mM unbuffered 
K2HPO4 and 5% glycerol overnight, with three buffer changes.  
Pig ETF was then purified using a series of chromatography steps on an FPLC system 
(Amersham Pharmacia Biotech ÄKTA). First, a negative chromatography step was employed 
using DEAE sepharose. ETF was recovered from the flow-through, easily recognized by its 
distinctive yellow color. Fractions containing ETF were pooled and subjected to chromatography 
on CM-Sepharose resin equilibrated with 10 mM Tris pH 8.5. After extensive washing, the ETF 
was recovered with a gradient from 0% to 100% 10 mM Tris with 100 mM NaCl pH 8.5.  
Fractions that fluoresced in ultraviolet light were collected and scanned on a spectrophotometer 
(Jasco V-650).  The absorbance ratio A270/A436 was calculated from the spectra to obtain the 
FAD ratio as an indicator of purity.  Fractions with a ratio less than 7 were pooled as fraction A.  
Fractions with a ratio above 7 were pooled as fraction B.  The pooled fractions were 
concentrated, the buffer was exchanged with 10mM Tris, and the samples flash frozen in liquid 
nitrogen and stored at -80 °C. The concentration of the stored protein was calculated using A436 
(flavin peak) and the extinction coefficient of 0.0134. 
2.2 BIOCHEMICAL COMPARISON OF RECOMBINANT LCAD PROTEINS 
The biochemical evaluation of the three LCAD enzymes was conducted using four 
methodologies.  First, steady-state enzyme activity was measured using the anaerobic ETF 
fluorescence reduction assay with saturating concentrations of various acyl-CoA substrates.  
Second, the same activity assay was used to determine catalytic efficiency by holding the amount 
of LCAD enzyme and ETF constant while varying substrate concentration.  Third, the first half-
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reaction (reductive) was followed by titrating the enzyme with substrates in the absence of the 
electron acceptor ETF.  Finally, stability of the LCAD proteins was determined by exposing the 
recombinant proteins to different temperatures and monitoring the proteins by absorbance 
spectroscopy.  These four techniques are described below. 
 LCAD steady-state enzyme activity assays. 
The anaerobic ETF fluorescence reduction assay takes advantage of the fact that porcine ETF 
loses intrinsic fluorescence upon accepting electrons from ACAD enzymes.  The assay is done 
under anaerobic conditions in sealed quartz cuvettes to eliminate secondary electron transfer to 
oxygen.  The assay buffer (55 mM Tris-HCl pH 8) is supplemented with glucose (0.6%), glucose 
oxidase (≥ 180 units/mg protein), catalase (≥ 1000 units/mg protein), and warming the cuvette 
for at least 2 minutes such that O2 is continually scavenged from the cuvettes.  Additionally, each 
cuvette is cycled with argon gas and vacuum for several minutes after being sealed with a rubber 
stopper in order to remove as much O2 as possible. 
LCAD is thought to be active against a range of acyl-CoA substrates.  Here, five 
substrates were used with chain lengths varying from 12 to 18 carbons, including one 
unsaturated substrate of 18 carbons that is physiologically relevant to FAO: C12-CoA, C14-CoA, 
C16-CoA, C18-CoA, and C18:1-CoA, all from Sigma (St. Louis, MO).  Substrate stocks were made 
in 2mM sodium acetate pH 5 and the concentration determined by dividing the A259 by the 
extinction coefficient (15.4).  Working solutions (1 mM) were degassed just before the assay 
with alternating cycles of argon and vacuum.  The assays were performed by adding enzyme 
(amount determined empirically for each LCAD enzyme, but usually about 100 -200 ng) and 
ETF (about 1 uM) to the cuvette needlewise. The reaction was started by injection of acyl-Co 
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substrate, and the change in fluorescence followed for 2 minutes on an FP-6300 Jasco 
spectrofluorometer excitation=340 nm, emission=490 nm).  A typical reaction is illustrated in 
Figure 7. The slope of the initial reaction was taken as shown by the blue line in Figure 7 and 
used to calculate specific activity using the equation [(-52.75) x (slope/intercept) / (µg protein 
used/1000)].  Each cuvette was also measured in the absence of substrate to determine the 
background, which was negligible. For steady-state measurements, 25 uM substrate was used.  
The amount of LCAD enzyme was adjusted for each substrate such that the initial slope was kept 
to < 1.0, such that experimental error due to the time lag between injecting substrate and starting 
the data collection software (~3 sec) was kept to a minimum.  All assays were measured in at 
least triplicate.  Statistical analysis was done by a one-tailed Student’s t-Test of two samples of 














The recombinant protein examined with substrates C18-CoA and C18:1-CoA were stored in 
ACAD Dialysis Buffer with FAD, and prepared by removing the unbound FAD using size 
exclusion columns (Bio-Rad Micro Bio-Spin ™ P-30 Gel Columns in Tris Buffer) as per 
manufacture instructions. 
 LCAD enzyme kinetics. 
A dilution series of C12-CoA was prepared in 2 mM sodium acetate pH 5, which yielded a 
substrate concentration range of 0.575 to 73.6 µM final concentrations in the ETF fluorescence 
reduction assay.  All substrate vials were degassed with alternating flows of argon and vacuum.  
Exogenous FAD was added to the LCAD enzymes with the storage buffer, any excess unbound 
FAD was removed using size exclusion columns (Bio-Rad Micro Bio-Spin ™ P-30 Gel Columns 
in Tris Buffer) as per manufacturer instructions.   
Slopes and Y-intercepts were determined as in the steady-state assays for each 
recombinant enzyme with each of the concentrations of substrate, and activity calculated per µM 
of the electron acceptor ETF rather than per unit of LCAD enzyme using the equation: -
((slope/intercept) / (µM ETF )) x (60/0.91).  Each substrate concentration was assayed at least in 
triplicate.  Then, Michaelis-Menten calculations were used (Graphpad Prism version 6.0) to 
determine the kinetic parameters of Vmax and Km for the curves of the enzymatic activity for each 
enzyme/substrate combination.  Finally, catalytic efficiency was expressed per unit of LCAD-
bound FAD to account for differences in FAD content between the various LCAD recombinant 
enzymes.  FAD content of the specific aliquots of each recombinant LCAD used for kinetics 
were determined using FAD absorbance (A445) and the extinction coefficient of 0.0139.  The 
catalytic efficiency was calculated by using the equation [(Vmax/FAD concentration)/60)/Km]. 
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 LCAD substrate titration assays (reductive half-reaction). 
Just as the ETF FAD loses fluorescence as it becomes reduced by accepting electrons, so does 
the FAD peak of each ACAD enzyme lose its absorbance (A445).  By titrating the recombinant 
LCAD enzyme with increasing amounts of substrate and measuring the responding loss of FAD 
absorbance, the rate of the reductive half-reaction (substrate binding and subsequent transfer of 
electrons to the FAD rings) can be followed.  As with the ETF fluorescence reduction assay, 
substrate titrations were performed anaerobically to eliminate electron transfer to oxygen.  After 
adding LCAD protein (1 mg/ml) in 500 µL of 25 mM potassium phosphate buffer, the cuvette 
was sealed, degassed and loaded into a spectrophotometer (Jasco V-650) blanked against 25 mM 
potassium phosphate.  An initial spectra was taken from 200 nm to 800 nm, then 1 µL aliquots of 
a 1.66 µM substrate were injected, and a new spectra collected after each addition.  The final 
substrate concentrations tested ranged from 0 to 48.35 uM.  The absorbance data were processed 
by subtracting the absorbance at 800 nm from the absorbance peak at 443 nm (FAD) for each 
concentration of substrate, then normalizing to baseline (absence of substrate).  The resulting 
FAD absorbance (A443) values were plotted against substrate concentration in Graphpad Prism 
6.0.  Recombinant enzymes hLCAD Wt, hLCAD K333Q, and mLCAD were all titrated with 
C12-CoA, while hLCAD Wt and hLCAD K333Q were further examined with C16-CoA and C18-
CoA.  The storage buffer of the enzyme titrated with C18-CoA contained exogenous FAD.  The 
unbound FAD was removed using size exclusion columns (Bio-Rad Micro Bio-Spin ™ P-30 Gel 
Columns in Tris Buffer) as per manufacturer instructions. 
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 Stability assays with recombinant LCAD proteins. 
An initial experiment was performed to test the stability by incubating recombinant proteins at 
37 °C for 48 hours and measuring the absorbance of the samples from 200 nm to 800 nm using a 
spectrophotometer (Thermo Scientific NanoDrop 2000) at varying time points.  However, an 
increase in absorbance near 345 nm was seen suggesting precipitation.  Therefore, the 
experimental design was adjusted. 
 The absorbance of each protein sample from 200 nm to 800 nm was measured using a 
spectrophotometer (Thermo Scientific NanoDrop 2000) to obtain baseline data.  Then, aliquots 
of protein were incubated for 30 minutes on ice, room temperature, 37 °C, and 55 °C.  Every half 
hour for two hours, four microliters of each protein were removed, centrifuged at 14,000 rpm for 
10 minutes at 20 °C to remove any precipitated material, and subjected to absorbance scanning 
from 200 nm to 800 nm.  Then, the remainder of the samples were incubated overnight (19 
hours).  The samples were centrifuged for 10 minutes for 14,000 rpm at 20 °C and the spectra 
were measured using the supernatants.  The stability was analyzed by measuring the peak of total 
protein near 280 nm to determine loss of protein due to precipitation at each temperature and 
time point. 
 Rescuing recombinant LCAD with exogenous FAD. 
The cofactor FAD provides visible color to the purified proteins.  However, recombinant 
hLCAD K333Q with a change from lysine to glutamine on all monomers is consistently more 
pale in color than recombinant hLCAD Wt.  Therefore, a loss of FAD was examined by 
determining the FAD ratios of recombinant hLCAD WT and hLCAD K333Q as described 
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above.  Furthermore, the rescue of any loss of FAD with exogenous FAD was examined.  
Purified recombinant proteins were incubated with a 100 µM concentration of FAD dissolved in 
purified water.  The concentration of purified protein was measured using BCA assay.  163.7 µg 
of hLCAD Wt and K333Q were each diluted in separate tubes to 47 µL with ACAD Dialysis 
Buffer.  A 100 µM final concentration of FAD dissolved in water was added to each tube.  An 
amount of purified water equal to the volume of FAD added was added to separate samples of 
163.7 µg hLCAD Wt and K333Q for control and all samples were incubated for 20 minutes at 37 
°C.  Unbound FAD was removed by passing all samples through size exclusion columns (Bio-
Rad Micro Bio-Spin ™ P-30 Gel Columns in Tris Buffer) as described above.  The activity of 
the protein was measured by performing ETF Assay with palmitoyl CoA as described above.  
Analysis of the enzymatic activity was done by a one-tailed Student’s t-Test of two samples of 
unequal variance. 
2.3 STRUCTURAL AND EXPRESSION DIFFERENCES BETWEEN MOUSE AND 
HUMAN LCAD 
In addition to the biochemical comparison of hLCAD and mLCAD, experiments were performed 
to evaluate expression levels in various tissues not previously studied. For example, human heart 
and muscle have been reported to contain little or no LCAD protein.  Here, I focused on liver, 
lung ATII cells, and other secretory epithelia similar to lung ATII cells (prostate, breast, etc).  
The levels of LCAD and VLCAD were determined to shed light on the relative roles of these 
two long-chain ACAD enzymes in human tissues.  Further, I analyzed the amino acid sequences 
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of hLCAD and mLCAD to look for differences that might explain species differences in 
enzymatic activity.  These methods are described in detail below. 
 Amino acid sequence alignment and three-dimensional structure analysis. 
The amino acid sequences for the hLCAD and mLCAD were obtained from NCBI 
(ncbi.nlm.nih.gov/protein) (NCBI Protein, 2015) (NCBI Protein, 2006).  Amino acid sequence 
alignment was performed using the program Blast (blast.ncbi.nlm.nih.gov/Blast.cgi) (NIH: 
NCBI, 2015).  Species differences with regards to the FAD  residues, substrate binding residues, 
and catalytic base were analyzed with the guidance of Dr. Al-Walid Mohsen on the three-
dimensional human LCAD structure using the program Insight II (Accelrys, Inc 2005).  The 
unpublished crystal structure for human LCAD was provided by Dr. Jung-Ja Kim (Medical 
College of Wisconsin). 
 Tissue expression of mouse versus human LCAD and VLCAD. 
I first performed a screen of LCAD and VLCAD protein levels in various human tissue lysates.  
Human tissue lysates of normal breast, kidney, liver, lung, pancreas, prostate, and thyroid were 
obtained from G-Biosciences, prepared by reconstituting in 30 µL nuclease free H2O to create a 
concentration of 5 µg/µL, and stored at -80 °C until use.  Kidney, liver, lung, and pancreas were 
collected from a C57BL/6J wild type mouse.  The tissues were homogenized in RIPA Buffer 
(Pierce) with protease inhibitors (Roche cOmplete, Mini) and phosphatase inhibitors (Boston 
BioProducts Phosphatase Inhibitors Cocktail-II).  Fifty µg of each tissue lysate were resolved on 
an SDS page gel (Bio-Rad TGX) and transferred onto a nitrocellulose membrane (Bio-RAD, 
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0.45 µm).  The membrane was blocked with 5% milk in TBS with 1% Tween-20 (TBS-T) for 1 
hour at room temperature, and then LCAD and VLCAD were visualized using primary rabbit 
anti-sera (kind gift of Dr. Jerry Vockley) at 1:2500 followed by chicken anti-rabbit antibody 
IgG-HRP (Santa Cruz Biotechnology, 1:5000) and chemiluminsence western blotting substrate 
(Pierce). 
 Abundance of LCAD and VLCAD in human and mouse hepatocytes. 
The relative abundance of LCAD and VLCAD in liver was further evaluated using primary 
murine and human hepatocytes (gifts of Dr. Lia Edmunds with Edward Prochownik, and Dr. 
Henry Dong respectively).  Hepatocyte cell pellets were lysed by sonication in RIPA buffer 
(Pierce) with protease inhibitors (Roche cOmplete, Mini).  Known amounts of recombinant 
LCAD and VLCAD proteins were mixed and used to create a dilution series that was loaded 
alongside the hepatocyte lysates as a standard curve.  Following SDS-PAGE and transfer to 
nitrocellulose, the membrane was cut and the upper and lower pieces immunoblotted for 
VLCAD (subunit molecular weight of 68 kDa) and LCAD (subunit molecular weight of 42 
kDa), respectively.  
Additionally, the lower portion of the membrane was stripped (Restore ™ PLUS, Thermo 
Scientific) according to manufacturer instructions and immunoblotted for β-actin  (Proteintech, 
IRP-labeled ACTB Monoclonal,1:20,000) as a loading control. 
The program Image J was used to perform densitometry to create the standard curve of 
known concentration of recombinant proteins and determine the unknown concentrations of 
LCAD and VLCAD in the hepatocyte lysates.  Statistical analysis was done by a one-tailed 
Student’s t-Test of two samples of unequal variance. 
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2.4 LYSINE ACETYLATION OF HUMAN LCAD 
Mouse LCAD is known to be subject to regulation by reversible lysine acetylation and the sirtuin 
enzyme SIRT3 (Bharathi S.S., et al. 2013).  Nothing is known about the effects of lysine 
acetylation on hLCAD.  This was investigated using two methodologies as described below. 
 Effects of chemical acetylation on recombinant hLCAD protein. 
Maximal lysine acetylation of purified recombinant hLCAD proteins was achieved as our 
laboratory previously reported for purified recombinant mLCAD (Bharathi S.S., et al. 2013).  
Briefly, approximately 100 µg of recombinant hLCAD Wt and recombinant hLCAD K333Q 
with a change from lysine to glutamine on all monomers were incubated with 15 mM sulfo-NHS 
acetate (Thermo Scientific) in 50 mM KPO4 pH 8 at room temperature for 1 hour.  Mock-treated 
proteins served as control. The acetylation reaction was neutralized by adding 5 µL of 1 M Tris 
pH 8.  Both the treated and mock-treated samples were dialyzed overnight in 20 mM Tris buffer 
pH 7.5 at 4 °C.  The dialyzed proteins were functionally assessed using the anaerobic ETF 
fluorescence reduction assay with palmitoyl CoA as substrate, as described above.  Statistical 
analysis of the enzymatic activity was done by a one-tailed Student’s t-Test of two samples of 
unequal variance.  Triplicates of the recombinant proteins for treated and mock-treated 
conditions were assessed for FAD ratio through spectroscopy as described above.  Statistical 
analysis was done by a one-tailed Student’s t-Test of two samples of unequal variance. 
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 Acetylation of hLCAD by aspirin in cultured cells. 
Aspirin, long known as a trigger of metabolic decompensation in patients with inborn errors of 
FAO (Tein I., 2015) (He M., et al.  2007), can chemically acetylate cellular proteins via its acetyl 
moiety (Wang J, et al. 2015). To test the effects of aspirin on hLCAD, HEK293 cells were 
transfected with a Flag-tagged hLCAD expression construct using Lipofectamine reagent 
(Thermo Fisher Scientific). The following day, half of the transfected cells were treated with a 
stock of aspirin dissolved in ethanol to a final aspirin concentration of 5 mM.  After 24 hrs, 
aspirin-treated and untreated control cells were harvested, lysed in RIPA buffer (Pierce) with 
protease inhibitors (Roche cOmplete Mini), centrifuged at 16,100 x g for 15 minutes at 4 °C, and 
the supernatant collected.  Immunoprecipitation using anti-Flag antibody was performed as 
follows.  First, lysates were pre-cleared by incubating with Protein A agarose for 1 hour at 4 °C.  
The beads were pelleted by centrifugation and discarded.  Then, the supernatant was mixed with  
5 µg of anti-Flag primary monoclonal antibody M2 (Sigma-Aldrich) and rotated at 4 °C for 1 
hour, followed by incubation with  Protein A agarose for 2 hours at 4 °C.  The agarose beads 
were pelleted, the supernatant removed and discarded, and the beads washed a total of four times 
in RIPA Buffer (Pierce).  Finally, hLCAD-Flag was eluted by heating in Laemmli buffer at 80 
°C for 10 minutes.  The beads were removed by centrifugation and the supernatant subjected to 
immunoblotting with anti-acetyl-lysine antibody (Cell Signaling Technologies, 1:2,500) as the 
primary antibody and goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, 1:5,000 as the 
secondary antibody.  Following exposure to film, the membrane was stripped as described above 
and probed for LCAD antigen as a loading control.  The program Image J was used to perform 
densitometry in triplicate for the untreated and aspirin treated samples.  Statistical significance 
was calculated by a one-tailed Student’s t-Test of two samples of unequal variance. 
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2.5 CORRELATION OF LCAD SNP K333Q WITH HUMAN LUNG PHENOTYPES 
A high-throughput qPCR-based assay (Taqman, Applied Biosystems) for genotyping the 
hLCAD missense SNP K333Q was validated as described below, and then applied to cohorts of 
children with lung disease.  Additionally, the correlation of K333Q with lung function indicators 
in the elderly was explored by mining the database from the Long Life Family Study (LLFS).  
Finally, the effect of SNP K333Q on antigen levels in vivo was determined using primary human 
ATII cells isolated from lungs that were genotyped for the SNP. 
 K333Q SNP genotyping assay and correlation with childhood lung phenotype. 
First, 149 DNA samples from human lungs not suitable for transplantation were obtained from 
Dr. Beata Kosmider (Jewish National, Denver, CO) and used to optimize the Taqman SNP 
genotyping assay (Applied Biosystems) for LCAD K333Q.  As control, two samples of lung 
DNA that had been genotyped by traditional Sanger Sequencing of exomes by GENEWIZ LLC 
were included.  TaqMan ® Genotyping Master Mix, MicroAmp ® Fast Optical 96-well plates, 
and optical adhesive film were obtained from Applied Biosystems.  Blank wells were prepared 
using water in place of template, while sample wells received approximately 10 ng of human 
genomic DNA. The plates were sealed, centrifuged briefly to eliminate air bubbles, and 
subjected to thermal cycling on a StepOnePlus Real-Time PCR thermal cycler (Applied 
Biosystems).  The program consisted of 95 °C for 10 minutes followed by 40 cycles of 95 °C for 
15 seconds and 60 °C for 1 minute.  The genotypes were called using the StepOne software. 
Both controls were genotyped in agreement with the previous results and the 149 lung DNA 
samples yielded allele frequencies that were statistically similar to expected values based on 
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online SNP databases.  The expected allele frequencies were determined from the general 
population based in the 1000 Genomes Project (NCBI. 1000 Genomes Browser, 2013).  
Statistical significance was calculated by a chi-squared test. 
Next, DNA samples from 142 full-term or near full-term Caucasian neonates with 
respiratory distress syndrome were obtained from Dr. Larry Nogee (Johns Hopkins University) 
and genotyped with the Taqman assay described above. An additional 60 cases of respiratory 
distress and age-matched controls were genotyped by Dr. Jennifer Wambach at Washington 
University.  Finally, 775 children (474 African American and 301 Caucasian) hospitalized for 
pneumonia were genotyped by Dr. Mary Dahmer at the University of Michigan using our 
reagents and protocol.  The expected allele frequencies were determined from the allele 
frequencies of Caucasian Utah residents and Americans of African Descent based in the 1000 
Genomes Project (NCBI. 1000 Genomes Browser, 2013).  Statistical significance was calculated 
by a chi-squared test. 
 Data mining using the Long Life Family Study (LLFS). 
The LLFS was funded by the National Institute on Aging, U.S. National Institutes of Health 
(grants U01AG023712, U01AG023744, U01AG023746, U01AG023749, and U01AG023755).  
The data of the LLFS is available using the accession number phs000397.v1.p1. in dbGaP.  The 
study consists of a cohort of 539 families (N=4,953) with siblings, spouses, as well as offspring, 
who were recruited from Denmark and the United States.  The mean age of the first-generation 
participants (e.g., siblings) was 90 years, whereas the mean age of the remaining participants was 
61.  The study participants were questioned regarding health, environment, and family history in 
addition to receiving biomedical testing.  All study participants were assayed for 2.5 million 
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SNPs  The SNP LCAD K333Q (rs2286963) was analyzed by Dr. Jatinder Singh for association 
with measures of lung function, including:  FEV1 (the volume of air expelled in the first second), 
FEV6 (the volume of air expelled in 6 seconds), FEV1/FEV6, LungD (lung disease), COPD 
(Chronic Obstructive Pulmonary disease), Asthma, and Bronchitis.  The analysis was 
simultaneously adjusted for age, sex, field center, and smoking status (yes or no).  Additionally, 
several markers of immune system function were examined for association with the SNP K333Q 
genotypes, including:  IL6 (Interleukin-6), WBC (white blood cell count), and CRP (C-reactive 
protein).  The replication cohort is Health Aging and Body Composition Study (Health ABC).  
The Health ABC study was partially funded by the Intra-mural Research Program of the National 
Institute on Aging (grants AE-2-1024, N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106). 
 Antigen-genotype correlation in primary human ATII cells. 
Lysates of primary ATII cells isolated from the same lungs genotyped for K333Q as described 
above were obtained from Dr. Beata Kosmider and immunoblotted for LCAD.  In total, six 
samples were obtained that were homozygous for the minor Q allele at residue 333 and six 
samples were obtained that were homozygous for the major K allele.  Five µg of total protein of 
each sample were resolved by SDS-Page (Bio-Rad TGX), transferred to nitrocellulose, and 
subjected to immunoblotting for LCAD and VLCAD as described above. Additionally, the 
membrane was stripped and probed with anti-ACAD9 antibody (gift of Dr. Jerry Vockley, 
1:2,500).  Finally the membrane was stripped and subsequently immunoblotted with anti-
acetyllysine antibody as described above.  The program Image J was used to perform 
densitometry.  Statistical significance was calculated by a one-tailed Student’s t-Test of two 
samples of unequal variance. 
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2.6 EVALUATION OF IMMUNE-RELATED PARAMETERS IN LCAD 
KNOCKOUT MOUSE LUNG 
To determine whether loss of LCAD in the lung exacerbates or protects against lung injury, 
LCAD knockout mice (N=4) and wild type (N=5) were infected with 100 plaque-forming units 
(PFU) of influenza virus in 50 ul of sterile PBS by oropharyngeal aspiration by Dr. Eric 
Goetzman and Dr. Chikara Otsubo (University of Pittsburgh).  The influenza A/PR/8/34 (H1N1) 
virus, propagated in chicken eggs, was obtained from Dr. John Alcorn (Children’s Hospital of 
Pittsburgh).  Seven days post-infection the mice were sacrificed and lung tissue was harvested, 
fixed, and stained by Dr. Goetzman and Dr. Otsubo for histology as scored by Dr. Alcorn.  
Statistical significance was calculated by a one-tailed Student’s t-Test of two samples of unequal 
variance. 
Further, surfactant protein-A (SP-A) antigen concentration was examined in mouse lung 
tissue and bronchial alveolar lavage fluid (BALF).  Lung tissue was collected from LCAD KO 
mice and strain-matched wild type controls.  Lysates were prepared by homogenizing the lung 
tissue using a bullet blender (Next Advance Bullet Blender ™ 24) in RIPA buffer (Pierce) with 
protease inhibitors (Roche cOmplete, Mini) and phosphatase inhibitors (Boston BioProducts 
Phosphatase Inhibitors Cocktail-II) as described above.  Western blotting for SP-A was 
conducted as described above for other antigens, using 50 μg of total lysate. BALF samples were 
blotted per unit of volume, with 40 µL loaded per lane.  The primary antibody was anti-SP-A 
(SFTPA1) (Proteintech, 1:300) and the secondary was chicken anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology, 1:600).  The program Image J was used to perform densitometry.  Statistical 
significance was calculated by a one-tailed Student’s t-Test of two samples of unequal variance. 
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3.0  RESULTS 
3.1 HUMAN LCAD VERSUS MOUSE LCAD 
Based on known disparities between human and mouse LCAD expression (high in mouse 
heart/muscle, absent in human heart/muscle), combined with the lack of bona-fide LCAD-
deficient patients, LCAD has been suggested to play little role in human FAO, or possibly to 
catalyze non-FAO functions in the human. Here, I have conducted an objective comparison of 
the human and mouse LCAD enzymes. The results of this comparison are expected to provide 
understanding into the biochemical role of human LCAD, the usefulness of the LCAD knockout 
animal model for investigating LCAD-related pathologies, and clues regarding the potential 
disease phenotype of an LCAD-deficient human.    
 Mouse LCAD is more active than human LCAD. 
If human LCAD fulfills a different biochemical role than the mouse enzyme, then its enzymatic 
properties may be altered. To address this question I utilized the simplest system possible:  
purified recombinant proteins. This system allowed for head-to-head comparison of the 
biochemical properties of mouse and human LCAD.   
First, the steady-state activities of mLCAD and hLCAD Wt recombinant proteins were 
measured using a range of acyl-CoA substrates from 12 carbons (C12-CoA) to 18 carbons (C18-
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CoA).  A monounsaturated C18 substrate was also included (C18:1-CoA), since this is a 
particularly abundant fatty acid in vivo, and to examine any differences in response to 
unsaturated fatty acids (Cox K.B., et al. 2001).  Each enzyme was assayed with each substrate in 
at least triplicate using the ETF fluorescence reduction assay under anaerobic conditions as 
described above.   
The steady-state specific activity with saturating substrate concentrations was 
significantly higher in mLCAD across all substrates tested (Figure 8).  Thus, this data suggests 








Figure 8:  Enzyme Activity Assay of hLCAD Wild Type and mLCAD with Substrates C12-CoA, C14-CoA, C16-
CoA, C18-CoA, and C18:1-CoA 
 
 Enzyme kinetics assays of human and mouse LCAD. 
The minimal difference in enzymatic activity between mLCAD and hLCAD when assayed with 
saturating concentrations of C12-CoA suggested that the two enzymes may be functionally 
equivalent with this substrate.  C12-CoA is a key chain length of substrate because it bridges the 
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gap between the activity profiles of VLCAD (C12 to C20) and MCAD (C4 to C16), both of which 
have detectable but low activity against C12-CoA (Souri M., et al. 1998) (Finocchiaro G., et al. 
1987) (Swigoňová Z., et al. 2009).  To further study species differences with regard to this 
substrate, a kinetics assay was performed by assaying enzymatic activity of recombinant 
enzymes over a wide and decreasing concentration range of C12-CoA and kinetic constants were 
calculated.  Activity in the kinetics assay was expressed in units of µM of ETF reduced per 
minute. The Vmax of hLCAD Wt with the substrate C12-CoA was 1.3 µM/min (Figure 9).  The 
Km, which represents the concentration of substrate at which the activity is half maximal, was 
6.9 µM, which is considerably higher than other ACAD enzymes when assayed with optimal or 
near-optimal substrates (Le W., et al. 2000).  In keeping with the steady-state assays, which 
essentially represent Vmax, mLCAD had a very similar calculated Vmax to hLCAD with C12-
CoA (1.2 µM/min), but the Km was considerably lower (2.4 µM) (Figure 9), indicating that 
mLCAD would be predicted to be more efficient at physiological substrate concentrations.  
Indeed, the calculated catalytic efficiency of mLCAD was five times higher than hLCAD Wt 









Figure 9:  Enzyme Kinetics Assay of hLCAD Wild Type and mLCAD with C12-CoA 
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 Investigating mechanisms behind the lower catalytic efficiency of hLCAD. 
Given the difference in Km for C12-CoA between mLCAD and hLCAD, I hypothesized that 
mLCAD may have a higher affinity than hLCAD Wt for acyl-CoA substrates. To compare the 
ability of the enzymes to bind substrates, an anaerobic substrate titration experiment was 
performed.  Under these conditions, electrons are removed from the acyl-CoA substrate and 
passed to the FAD rings, and as it becomes reduced, the FAD loses its characteristic absorbance 
near 443 nm.  At the same time, a broad band forms at around 570 nm, which represents the 
charge-transfer complex, in which the reduced LCAD enzyme, still bound to enoyl-CoA product, 
awaits resolution of the complex via transfer of electrons to ETF (Figures 10 and 11).  The focus 
of this assay is the reduction of FAD represented by the decrease in the absorbance of FAD near 
443nm normalized by the absorbance at 800 nm.  Surprisingly, when the FAD absorbance peak 
values from Figures 10 and 11 were plotted against substrate concentration (Figure 12), it was 
clear that the two enzymes had similar abilities to reduce FAD and similar affinities for the C12-
CoA substrate.  Thus, differences in substrate binding and reducing the FAD do not explain the 








































Figure 12:  Substrate Titration of Human LCAD Wild Type and Mouse LCAD with 0 µM to 48.35 µM of C12-
CoA 
 Stability of hLCAD and mLCAD. 
Another mechanism explored to explain the lower catalytic efficiency and enzymatic activity of 
hLCAD was protein stability.  The lower stability of hLCAD could explain lower function in the 
activity assays. In preliminary experiments it was noted that the absorbance spectra of 
recombinant hLCAD changed with extended incubations at 37 °C, particularly with an increase 
in absorbance at 345nm from an absorbance of approximately 0.05 at 0 hours for recombinant 
hLCAD Wt enzyme to approximately 0.15 at 48 hours and an absorbance of approximately 0.05 
at 0 hours for recombinant hLCAD K333Q enzyme to approximately 0.35 a t 12 hours, 

















Figure 14:  Spectra of hLCAD K333Q Incubated at 37°C for 48 Hours 
 
Therefore, a simple stability assay was designed in which hLCAD and mLCAD were 
incubated at 0 °C, room temperature, 37 °C, and 55 °C for increasing time periods.  At each time 
point, the proteins were centrifuged to remove precipitated protein and subjected to absorbance 
scanning. The resulting absorbance scans did not show the abnormal increase in absorbance near 
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345 nm indicating the that precipitated proteins were successfully removed (see Appendix A). 
The A280 peaks from these scans, chosen to represent the total soluble LCAD protein remaining 
at each time point, were normalized to absorbance at 0 hours and plotted against time of 
incubation (Figures 15 and 16).  In these latter plots, it is clear that some hLCAD protein is lost 
from solution after an overnight incubation at 37°C while this is not seen for mLCAD.  In 
contrast, when exposed to the severe temperature of 55°C, both proteins quickly precipitate, and 
to similar degrees (Figure 17).  Thus, hLCAD seems to be modestly less stable than mLCAD, 
but this is apparent only after extensive incubation (overnight) at 37°C, and therefore does not 
likely explain the reduced catalytic efficiency in the kinetics assays, which involve only short-









Figure 15:  Stability Assay of hLCAD Wt at 0°C, Room Temperature, and 37°C for 0 Hours, 1 Hour, 1.5 












Figure 16:  Stability Assay of mLCAD at 0°C, Room Temperature, and 37°C for 0 Hours, 0.5 Hours, 1 Hour, 











Figure 17:  Stability Assay of hLCAD Wt and mLCAD at 55°C for 0 Hours, 0.5 Hours, and 1 Hour 
Normalized to 0 Hours 
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 Structural differences between mouse and human LCAD. 
Finally, the primary amino acid sequences and the three-dimentional crystal structure of hLCAD 
solved by collaborator Dr. Jung-Ja Kim (unpublished), were analyzed for clues regarding the 
enhanced biochemical function of mLCAD compared to hLCAD.  Mouse LCAD and human 
LCAD are 87% identical and 93% similar in amino acid sequence (Figure 18) 
(blast.ncbi.nlm.nih.gov/Blast.cgi).  Analysis of the crystal structure of human LCAD with the 
guidance of Dr. Al-Walid Mohsen bound with C12-CoA revealed that fourteen amino acids were 
within approximately 3 Å of the C12-CoA substrate, indicating a potential role in binding.  One 
of the substrate-binding amino acids was found to be valine in human LCAD and a leucine in 
mouse LCAD (Figure 18).  Forty-three amino acid residues were found to be within about 3 Å of 
the FAD cofactor, indicating a potential role for binding, and 40 out of 43 of these amino acid 
residues are identical between mouse and human LCAD (Figure 18).  The three remaining FAD 
binding residues that were not identical between mLCAD and hLCAD were residues 205, 253, 
and 327.  Two of theses—residues 205 and 253—are conservative substitutions (threonine to 
serine and isoleucine to leucine) while residue 327 is a methionine in the mouse sequence and 
leucine in the human sequence.  This latter substitution, while not as conservative as the other 
two, was not predicted to be deleterious when analyzed by the prediction software SIFT.  SIFT is 
a computational algorithm that uses information on the degree of conservation of amino acids in 
related sequences as well as the properties of amino acids, to assess whether an amino acid 
change has detrimental effects on enzyme or protein function (SIFT, 2015).  Finally, the catalytic 
base and lysine 333 are conserved between mouse and human LCAD indicating importance of 
these sites as they remain conserved across species (Figure 18).  Therefore, the analysis of the 
two LCAD sequences did not reveal any amino acid differences to suggest that the human 
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enzyme has a different function than the mouse enzyme.  However, the differences in the amino 














Figure 18:  Amino Acid Alignment of Mouse and Human LCAD 
 Differences in LCAD expression between mice and humans. 
 LCAD is not appreciably expressed in human muscle or heart tissue in which FAO is an 
important source of energy (He M., et al. 2007).  On the other hand, hLCAD is expressed in 
ATII cells in the lung (Goetzman E.S., et al. 2014).  LCAD has also been implicated in the 
pathogenesis of human prostate and breast cancers (Xie, B.-X., et al. 2011) (Hill, VK, et al., 
2011).  Therefore, I hypothesized that LCAD may have a role in human tissues not typically 
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reliant on FAO, particularly in secretory epithelial cells such as ATII cells or the epithelia of the 
breast and prostate.  To examine the possible role of LCAD in these secretory tissues, the 
expression of LCAD was experimentally examined in human tissue lysates.  The expression of 
VLCAD was examined concurrently given that the substrate specificity of VLCAD overlaps 
with LCAD, so possible compensation for a deficiency of LCAD could be determined and to 
gain insight into the relative role of these two long-chain ACAD enzymes.  Equal amounts of 
total protein lysates from human breast, kidney, liver, lung, pancreas, prostate, and thyroid tissue 
(G Biosciences) as well as mouse kidney, liver, lung, and pancreas tissue were Western-blotted 
with anti-LCAD and anti-VLCAD antibodies, with Ponceau staining as a loading control (Figure 
19).  Contrary to my hypothesis, hLCAD was most abundantly expressed in the liver, followed 
by kidney, lung, and pancreas. Human breast, prostate, and thyroid showed little or no detectable 
LCAD protein. VLCAD was similarly highly expressed in human liver, kidney, and pancreas 
with little or no antigen in breast, prostate, or thyroid.  LCAD appeared to dominate over 
VLCAD in human lung tissue, as only trace amounts of the short isoform of VLCAD were 
detectable in human lung lysate, and no visible VLCAD antigen in mouse lung tissues (Figure 
19).  Also, there seems to be more VLCAD antigen in human pancreas lysate than mouse lysate.  
Additionally, there seems to be more LCAD in the liver than in the kidney in human tissue 
lysates, but similar amounts of LCAD antigen in mouse kidney and liver tissue lysates (Figure 














Figure 19:  Western Blots of LCAD and VLCAD Antibodies of 50 µg of A) Mouse and B) Human Tissue 
Lysates 
 Quantification of LCAD and VLCAD in human and mouse hepatocytes. 
As Figure 19 shows, mice and humans both appeared to co-express LCAD and VLCAD in the 
liver. This may be of clinical significance as it indicates that hLCAD may be able to compensate 
for the loss of VLCAD in VLCAD-deficient patients. To further investigate this co-expression, 
an experiment was designed to quantify the amount of LCAD and VLCAD antigen in the 
primary hepatocytes isolated from humans and mice.  Hepatocytes were examined as they 
account for the largest percentage of cell population of the liver, and are an important site of fatty 
acid metabolism (Wang Y. and Hay D.C. 2016) (Fox I.J., et al. 1998).  A standard curve of 
known amounts of recombinant LCAD and VLCAD from 20 ng to 80 ng were immunoblotted 
alongside 25 μg of human and mouse hepatocyte lysates (Figure 20). LCAD antigen in primary 






Figure 20:  Western Blot of LCAD and VLCAD in 25 µg of Human and Mouse Hepatocyte Lysates 
 
The program Image J was used to quantify the standard curve of each recombinant 
protein with densitometry and determine the unknown quantity of LCAD and VLCAD in the 
hepatocyte lysates (Figure 21). Human hepatocyte lysates had about half as much LCAD antigen 
per μg of total protein than mouse hepatocytes (1.9ng of LCAD per μg versus 3.5 ng per μg), 











Figure 21:  Quantification of ng of LCAD and VLCAD per µg of Hepatocyte Lysate 
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 Conclusions. 
The amino acid sequences of mouse and human LCAD are largely conserved, and ability of 
human and mouse LCAD to bind a substrate and reduce FAD are similar.  However, the 
phenotype of LCAD knockout mice resembles the phenotype of human VLCADD (Chegary M., 
et al. 2009) (Cox K.B., et al. 2001) (Kurtz D.M., et al. 1998).  Furthermore, some investigators 
have suggested that mLCAD and hLCAD are not functional equivalents (Maher A.C., et al. 
2010).  My results indicated that the enzyme activity of mLCAD is higher than hLCAD Wt 
activity for all substrates tested (Figure 8), suggesting that the two enzymes are not functionally 
equivalent.  This was further supported by kinetic assays that demonstrated that mLCAD has 
considerably higher catalytic efficiency than hLCAD Wt (Figure 9).  Furthermore, mLCAD was 
somewhat more stable than hLCAD Wt at 37 ºC (Figure 15) (Figure 16).  Finally, the tissue 
expression of LCAD and VLCAD were shown to be different between human and mouse 
primary hepatocytes.  Surprisingly, hLCAD is more abundant in human hepatocytes that 
previously suggested in the literature (half as abundant as in mouse hepatocytes). A much larger 
differential between species was noted for VLCAD, which appears to be weakly expressed in the 
mouse. This may explain why VLCAD knockout mice have a mild phenotype.  Human 
hepatocytes rely somewhat more on VLCAD than LCAD, whereas mouse hepatocytes rely very 
heavily on LCAD (Figure 20) (Figure 21).  When taken together, these studies suggest that 
LCAD may not serve the same function in humans as it does in mice,  Further, it suggests that 
the LCAD/VLCAD knockout models may not be representative of their respective human 
phenotypes. 
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3.2 HUMAN LCAD WILD TYPE AND THE CONSEQUENCES OF HUMAN LCAD 
K333Q 
While there have been no identified patients in the literature, our laboratory has previously 
described two cases of SUID with no measurable LCAD antigen in the lung.  Both were 
homozygous for a common polymorphism, K333Q.  Although the amino acid sequence 
alignment shows that the lysine in SNP K333Q is not an FAD binding residue, it is adjacent to 
the FAD binding residue, Histidine 332 (Figure 18).  The crystal structure reveals that lysine 333 
(K333) is about 6.06 Å away from the FAD in the crystal structure.  Therefore, a change to 
glutamine at site 333 may have indirect consequences to FAD binding and/or enzymatic activity 
in human LCAD.  Additionally, lysine 333 is conserved between mouse and human LCAD 
(Figure 18).  It was therefore hypothesized that this polymorphism may be detrimental to LCAD 
function.  Furthermore, because the lung represents a tissue where hLCAD is dominant with little 
VLCAD co-expression, it was hypothesized that K333Q may be a risk factor for human lung 
disease.  These hypotheses were investigated through examination of the crystal structure, 
biochemical characterization of recombinant LCAD K333Q, and genotyping of disease 
populations for the SNP K333Q. 
 Human LCAD crystal structure. 
The crystal structure of human wild-type LCAD containing C12-CoA in the substrate-binding 












Figure 22:  Crystal Structure of Human LCAD Wild Type:  Four subunits forming a homotetramer are 
shown.  The yellow ring structure are FAD bound in the active site, and the orange ball strutures are bound 
substrate 
 
Analysis of the structure reveals that, like other ACADs, LCAD forms a homotetramer 
with the binding pockets of the active sites toward the center, where the vital FAD and the acyl-
CoA substrate are bound.  As described previously, analysis of the crystal structure revealed that 
while each monomer is associated with an FAD cofactor, FAD binding is cooperative, such that 
each FAD is bound by amino acids from three different subunits of the LCAD homotetramer.  
Twenty-five amino acids from one subunit have the potential to bind FAD, with further 
contribution from 16 amino acids on the adjacent subunit and two amino acids (Gln328 and 
Val330) from a third subunit of the homotetramer.  Importantly, the amino acid residue K333 
that changed from a lysine to a glutamine in the SNP K333Q is adjacent to histidine 332 that is 
predicted to bind FAD.  This analysis suggests that any alteration at residue K333, i.e., 
polymorphism K333Q, may have deleterious effects on enzymatic assembly and/or function. 
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 Enzyme activity assays of human LCAD wild type and K333Q. 
Given the proximity of residue K333 to the active site of human LCAD, I hypothesized that the 
polymorphism K333Q would indeed inhibit the enzymatic function of hLCAD.  This hypothesis 
was examined experimentally using the steady-state ETF fluorescence reduction assay with 
recombinant enzymes.  The sequence of the plasmid for the recombinant enzyme, hLCAD 
K333Q, changes the wild type lysine to a glutamine at site 333 for all monomers of the purified 
protein.  Compared to recombinant hLCAD, recombinant hLCAD K333Q demonstrated 
significantly reduced enzymatic activity for multiple acyl-CoA substrates including C12-CoA, 










Figure 23:  Enzyme Activity Assay of hLCAD Wild Type and hLCAD K333Q with C12-CoA, C14-CoA, C16-





 Enzyme kinetics assays of recombinant hLCAD and hLCAD K333Q. 
The data in Figure 24 indicated that the polymorphic LCAD enzyme is less active than wildtype 
hLCAD when assayed with saturating substrate concentrations. To further probe this difference, 
kinetic assays were performed using a range of C12-CoA (near 0.6 µM to near 40 µM).  To 
account for any differences in FAD content, the activity data for the kinetics assay was 
normalized to the FAD absorbance (443 nm) rather than to protein concentration.  The Vmax of  
wild-type hLCAD was 1.3 µM/min and the Km for C12-CoA was 6.9 µM (Figure 24).  
Surprisingly, hLCAD K333Q showed enhanced activity with lower substrate concentrations, and 
thus, while the Vmax was similar to the wild-type enzyme (1.2 µM/min) the Km was considerably 
lower (2.2 µM).  As a result of the lower Km, the calculated catalytic efficiency of the K333Q 
mutant was higher than hLCAD Wt (2.5 µM-1sec-1 versus 0.7 µM-1sec-1) (Figure 24). This result 
indicates that the hLCAD wild type seems to be less efficient at catalyzing the reaction with C12-









Figure 24:  Enzyme Kinetics Assay of hLCAD Wild Type and hLCAD K333Q with C12-CoA 
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 Substrate titration assays human LCAD wild type and K333Q. 
The reductive half-reaction of LCAD can be assessed by incubating the enzyme under anaerobic 
conditions with increasing amounts of substrate.  Under these conditions, electrons are removed 
from the acyl-CoA substrate and passed to the FAD rings, and as it becomes reduced, the FAD 
loses its characteristic absorbance at 443 nm.  At the same time, a broad band forms at around 
570 nm, which represents the charge-transfer complex, in which the reduced LCAD enzyme, still 
bound to enoyl-CoA product, awaits resolution of the complex via transfer of electrons to ETF.  
To determine if K333Q alters the reductive half-reaction, the recombinant enzyme with a change 
from lysine to glutamine at site 333 for all monomers (hLCAD K333Q) and its wild-type 
counterpart were titrated with increasing amounts of three different acyl-CoA substrates.  An 
example of the creation of the charge-transfer complex as demonstrated by the increase in 
absorbance at 570 nm is seen in Figure 25.  Figure 25 represents the formation of the charge-
transfer complex by showing the increasing absorbance of the peak at 570nm normalized by 
subtracting the absorbance at 800nm.  The focus of this assay is the reduction of FAD 
represented by the decrease in the absorbance of FAD near 443nm normalized by the absorbance 
at 800nm.  For all three substrates tested, C12-CoA, C16-CoA, and C18-CoA, recombinant hLCAD 
K333Q did not reduce in absorbance as much as hLCAD Wt enzyme (Figure 10) (Figures 26-
33).  Therefore, hLCAD K333Q had decreased ability to bind substrates or to reduce the cofactor 
FAD as compared to hLCAD wild type. One possible interpretation is that the four subunits of 
LCAD, each of which normally contains an FAD, work cooperatively for maximum abstraction 
of electrons and formation of the charge-transfer complex.  Partial loss of FAD combined with 
de-stabilization at the monomer-monomer interfaces, caused by K333Q, may block inter-subunit 











Figure 25:  Charge-Transfer Complex Measured by Absorbance of 570nm-800nm of hLCAD K333Q with 0 






























































































Figure 33:  Substrate Titration of hLCAD Wt and hLCAD K333Q with C18-CoA from 0 µM to 48.35 µM 
 
 Stability assay of human LCAD wild type and K333Q. 
Given the position of K333 at the monomer-monomer interface and its proximity to important 
FAD-binding residues such as H332, I hypothesized that substitution K333Q may destabilize the 
LCAD homotetramer.  Indeed, the stability assay of recombinant hLCAD wild type and hLCAD 
K333Q incubated at 0 °C, room temperature, 37 °C, and 55 °C for 19 hours showed that hLCAD 
Wt seems to be more stable than hLCAD K333Q.  At 0 °C and room temperature there was no 
precipitation in either hLCAD Wt or K333Q after 19 hours of incubation (Figure 15) (Figure 34).  
However, it was shown that at 37 °C there was precipitation of both hLCAD Wt and K333Q 
proteins, but the effect was greater for the mutant K333Q.  A greater percentage of hLCAD 
K333Q protein precipitates at 37 °C with the absorbance of the peak near 280 was reduced by 
approximately 10% after 19 hours and as compared to approximately 30% for hLCAD K333Q  
(Figure 15) (Figure 34).  Additionally, with incubation at 55 °C, both hLCAD Wt and hLCAD 
K333Q showed rapid precipitation beginning around 0.5 hours of incubation.  After 1 hour at 55 
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°C the absorbance peak near 280 nm was reduced by approximately 30% for hLCAD wild type 










Figure 34:  Stability Assay of hLCAD K333Q at 0°C, Room Temperature, and 37°C for 0 Hours, 0.5 Hours, 1 





















Figure 35:  Stability Assay of hLCAD Wt and hLCAD K333Q at 55°C for 0 Hours, 0.5 Hours, and 1 Hour 
Normalized to 0 Hours 
 Rescuing loss of FAD with exogenous FAD. 
The bound FAD cofactor provides a distinct yellow color to purified recombinant LCAD, which 
was noticeably paler in for purified hLCAD K333Q as compared to purified recombinant 
hLCAD Wt.  This suggests a lower FAD content in the K333Q mutant protein, which would 
explain the lower enzymatic activity of hLCAD K333Q and impaired reduction of FAD and 
formation of the charge-transfer complex. To examine this hypothesis, I performed an 
experiment to measure the FAD ratio through spectral scans of the recombinant protein.  The 
FAD ratio is calculated as the ratio of FAD as measured by the absorbance near 445 nm by the 
total protein as measured by the absorbance near 280 nm.  An FAD ratio of approximately 8 
indicates normal binding of FAD and an FAD ratio above 10 indicates of loss of the FAD 
cofactor.  Lost FAD cofactors can be replaced through incubation of purified LCAD protein with 
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exogenous FAD (Nagao M. and Tanaka K. 1992).  The spectra of recombinant hLCAD Wt and 
hLCAD K333Q were obtained to calculate the FAD ratios (Figure 36), and indeed, mutant 
K333Q was associated with a partial loss of FAD from the protein.  Then, it was determined if 
the loss of FAD, as well as the reduced enzymatic activity, could be rescued with incubation of 
exogenous FAD.  Both Wt hLCAD and the mutant K333Q showed significantly improved FAD 
ratios following incubation with exogenous FAD (Table 1), and in keeping with this, enzymatic 
activity was also increased for both proteins (Figure 37).  The incubation of recombinant hLCAD 
with exogenous FAD decreased the FAD ratios of hLCAD by reducing the ratios of both 
hLCAD Wt from 8.16 to 6.64 and hLCAD K333Q from 12.11 to 9.70 (Table 1).  Exogenous 
FAD significantly increased the enzymatic activity of both hLCAD wild type and hLCAD 
K333Q (Figure 37).  However, even after FAD rescue, the enzymatic activity of hLCAD K333Q 






































 FAD ratio and enzymatic activity with chemical acetylation. 
Our lab has previously shown that acetylation inhibits the activity of recombinant mLCAD and 
that this effect maps to lysine residues 318 and 322 (Bharathi S.S., et al. 2013).  Specifically, 
acetylation of K318/K322 shifted FAD in the mLCAD active site, and eliminating the positive 
charge at these residues caused a loss of FAD similar to that seen in LCAD K333Q. K333Q 
essentially mimics lysine acetylation by eliminating the positive charge. Therefore, I predicted 
that the presence of K333Q would exacerbate the negative effects of lysine acetylation at nearby 
K318 and K322.  To test this, wild-type hLCAD and hLCAD K333Q recombinant proteins were 
chemically acetylated with sulfo-NHs-acetate (SNA) and the resulting effects on function and 
FAD content were measured. The FAD ratio of both proteins increased following lysine 
acetylation, indicating a partial loss of FAD, although these changes did not reach statistical 
significance the wildtype protein shows normal binding of FAD with an FAD ratio near 8, 
recombinant hLCAD K333Q has an increased FAD ratio of about 9 indicating reduced binding 
of FAD (P = 0.055 and P = 0.1973 respectively) (Figure 38).  Chemical acetylation significantly 
reduced the enzymatic activity of hLCAD Wt (P = 6.05E-4) and hLCAD K333Q (P = 0.011).  
The SNP K333Q was even more sensitive to the loss of enzymatic activity with chemical 
























Figure 39:  Enzymatic Activity Assay of Chemically Acetylated and Unacetylated hLCAD Wt and hLCAD 
K333Q with C16-CoA 
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 Transfected HEK293 cells treated with aspirin. 
Chemical acetylation was shown to reduce the enzymatic activity of hLCAD K333Q.  
Additionally, acetylation has been shown to regulate mitochondrial proteins (Baeza J., et al. 
2016).  Therefore, I hypothesized that acetylation may regulate the function of LCAD in vivo.  
An experiment was designed in order to examine the acetylation of human LCAD in vivo 
through the contribution of the acetyl group of acetylsalicylic acid. HEK293 cells were 
transfected with an hLCAD-Flag expression construct and then treated with 5 mM aspirin. 
Acetylation of LCAD was determined by immunoprecipitating with anti-Flag followed by 
western blotting with anti-acetyllysine antibody (Figure 40).  Densitometry using the program, 







Figure 40:  Western Blot of anti-Flag Immunoprecipitation of hLCAD Wt Transfected HEK293 Cells 
















Figure 41:  Densitometry of Acetyllysine Antigen in FLAG IP of hLCAD Wt Transfected HEK293 Cells 
 Acetylation in primary human pneumocytes. 
Acetylation was previously shown in our lab to reduce the enzymatic activity of recombinant 
mouse LCAD (Bharathi S.S., et al. 2013).  I additionally showed that chemical acetylation 
inhibits the enzymatic activity of recombinant human LCAD (Figure 39) and that aspirin 
acetylates hLCAD Wt in vivo (Figure 41).  Therefore, I hypothesized that acetylation of LCAD 
may contribute to the regulation of LCAD in human tissues.  In order to examine a possible role 
of the acetylation of LCAD in human tissues, an experiment was performed to determine 
whether there is acetylation of proteins occurring in human primary ATII cells where LCAD is 
known to be highly expressed (Goetzman E.S., et al. 2014).  Western blot analysis of 5 µg of 
primary alveolar type II cell lysates revealed that acetyllysine antigen is indeed present in 









Figure 42:  Western Blot of Acetyllysine Antigen in 5 µg of Primary Alveolar Type II Cell Lysates 
 LCAD in human primary pneumocytes homozygous for the SNP K333Q and 
homozygous wild type. 
Based on my biochemical characterization of recombinant hLCAD K333Q, I hypothesized that 
the SNP K333Q is detrimental.  LCAD is specifically expressed in the ATII cells of the lung in 
humans (Goetzman E.S., et al. 2014).  Therefore, I hypothesized that the SNP K333Q will 
negatively impact the expression of LCAD in human primary ATII cells.  Lysates of primary 
ATII cells with a known genotype of LCAD K333Q were obtained from collaborators in order to 
examine the amount of LCAD antigen.  The amount of VLCAD and ACAD9 antigen were 
examined in order to confirm that there was no appreciable expression of ACADs that may 
compensate for a lack of LCAD.  Western blotting of 5µg of primary ATII cell lysates showed 
significantly reduced LCAD antigen in alveolar type II cell lysates from six people who were 
homozygous for the SNP, K333Q, as compared to type II cells from six people who were 










Figure 43:  Western Blot of LCAD, VLCAD, ACAD9, and β-actin Antigens in 5 µg of Primary Alveolar Type 
II Cell Lysates 
 
Densitometry (leaving out the last lane of homozygous wild type due to anomalous 
protein loading) revealed that LCAD antigen is significantly reduced by about 80% in ATII cells 
homozygous for the K333Q SNP (Figure 44).  VLCAD and ACAD9 antigen were observed in 
human primary ATII cells upon longer film exposures, and the abundance of these proteins was 
quite variable.  I conclude that while they are present, their abundance is low and they likely 

















Figure 44:  Densitometry of LCAD Antigen in a Western Blot of 5 µg of 6 Human Primary Alveolar Type II 
Cell Lysates K/K and 5 Q/Q Lysates 
 Association of SNP K333Q with a lung phenotype. 
Based on the observation that K333Q (hereafter the “Q allele”) appears to destabilize the 
hLCAD protein in vivo, I hypothesized that a phenotype of LCADD might include a phenotype 
of lung disease.  Furthermore, given that the Q-allele form of SNP K333Q reduced the enzymatic 
activity of the recombinant enzyme, inhibited the creation of the charge-transfer complex, 
reduced the stability of the enzyme, and reduced the amount of LCAD antigen, I also 
hypothesized that the Q-allele would be detrimental and contribute to LCADD.  Specifically, I 
hypothesized that the Q-allele would be associated with decreased lung function or increased risk 
of lung disease.   Therefore, I assessed whether genotypes at SNP K333Q were associated with a 
variety of lung phenotypes from four different populations:  
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(1) Lung tissue from lungs not suitable for transplantation (N=149) from Drs. Kosmider and 
Wang 
(2) Caucasian children with respiratory distress syndrome (n= 142) from Dr. Nogee at Johns 
Hopkins University 
(3) Children with pneumonia (n= 775) from Dr. Dahmer at the University of Michigan 
(4) Adults from the Long Life Family study (n=4223) 
Among the set of 149 lung samples (not suitable for transplantation), genotype 
frequencies of the three genotypes at SNP K333Q did not differ from the expected frequencies 
(Table 2; P=0.13).  The expected genotype frequencies were based on population allele 
frequencies of the general population obtained from the 1000 genome project (NCBI. 1000 
Genomes Browser, 2013).  This result is consistent with a priori expectations because the 
samples were obtained from the general population.  
 
Table 2:  K333Q SNP Genotyping of Lungs not Suitable for Transplantation 
 
Genotype frequencies for SNP K333Q in 142 Caucasian children with respiratory distress 
syndrome also did not differ from population frequencies, P = 0.33 (Table 3), indicating that the 
SNP is not associated with respiratory distress, however, the sample size is small.  
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The genotyping of SNP K333Q done by Dr. Mary Dahmer in 775 children that were 
hospitalized for pneumonia also revealed no significant difference in genotype frequencies when 
the genotype frequencies of children who had additional outcomes of mechanical ventilation 
(MV), acute lung injury (ALI), and/or asthma were compared by chi-squared to the genotype 
frequencies of those who did not have an outcome beyond being hospitalized for pneumonia 
(African American; MV P = 0.976, ALI P = 0.960, and asthma P = 0.987) (Caucasian; MV P = 










Table 4:  K333Q Genotyping of Children (African American) Hospitalized for Pneumonia.  A) Children Who 
Had an Outcome of Mechanical Ventilation B) Children Who Had an Outcome of Acute Lung Injury C) 











Table 5:  K333Q Genotyping of Children (Caucasian) Hospitalized for Pneumonia.  A) Children Who Had an 
Outcome of Mechanical Ventilation B) Children Who Had an Outcome of Acute Lung Injury C) Children 










However, based on allele frequencies from the 1000 genome project there was a 
significant difference from Hardy-Weinberg Equilibrium in both the Caucasian and African 
American groups of children hospitalized with pneumonia (Caucasian; P = 5.94E-3 and African 
American; P = 2.49E-2) (NCBI. 1000 Genomes Browser, 2013).  There are more homozygous 
wildtype than expected (Caucasian; 153 observed and 127.8 expected) (African American; 339 
observed and 312.1 expected) and there are fewer heterozygotes than expected (Caucasian; 110 
observed and 136.7 expected) (African American; 124 observed and 145.0 expected).  In the 
Caucasian group there are more homozygotes for the Q allele than expected (38 observed and 
36.6 expected), whereas in the African American group there are fewer homozygotes for the Q 
allele (11 observed and 16.8 expected) (Table 6) (Table 7).  However, a larger study with 
controls would need to be done to confirm any difference from Hardy-Weinberg Equilibrium. 














In the Long Life Family Study (N=4223), seven lung function traits were tested for 
association with genotypes at SNP K333Q (rs2286963) overall individuals and by different 
subgroups.     
As can be seen in the LLFS All group (Table 8), individuals with the Q allele had 
increased lung function, as measured by FEV1 (beta = 29.1, P= 0.019).  Furthermore, this 
improved function in the overall group appeared to be due to the improved function among the 
controls (beta = 79.0, P = 0.006).  These results, however, were not statistically significant given 
the number of tests performed.   
 










3.3 ROLE OF LCAD IN THE IMMUNE SYSTEM 
 Evidence for association of LCAD with the immune system in LCAD -/- mice. 
Although my initial hypothesis was that the “Q” allele of SNP K333Q would have a detrimental 
effect, results from two of the population studies contradict this and may indicate that it actually 
has a beneficial effect.  Therefore, LCAD’s natural function may be detrimental in specific 
environments, such that reducing LCAD activity confers a benefit.  One such specific context 
may be the immune response, which is known to involve bioenergetic switching to facilitate 
rapid immune cell proliferation (Gerriets V.A., et al. 2015).  Additionally, LCAD is expressed in 
ATII cells which are involved in the innate immune response to inhaled pathogens (Goetzman 
E.S., et al. 2014) (Crestani B., et al. 1994) (Akgün J., et al. 2015) (Lu R., et al. 2012).  Because 
both mouse and human lung rely predominantly upon LCAD over VLCAD, the LCAD knockout 
mouse may serve as a useful model to investigate the role of LCAD in the lung (Figure 20).  
Therefore, LCAD knockout mice (N=4) and wild-type controls (N=5) were infected with 
influenza by the pathologist Dr. John Alcorn to assess effects on the lung immune response.  Dr. 
John Alcorn then blindly scored the inflammation from 0 being the least inflammation to 4 being 
the worst.  Lungs from LCAD knockout mice showed significantly decreased inflammation as 
compared to wild type mice (Figure 45) (Figure 46) (Figure 47).  Extrapolating to the findings 
from human cohorts with the Q allele, reduced lung damage as a consequence of reduced 
inflammation could explain the improved lung function seen in those with the SNP K333Q in the 
































Figure 47:  Pathology Scores of Parenchymal Lung Section from 0 (Least Inflammation) to 4 (Highest 
Inflammation) 
 Association of the SNP K333Q with the immune system in the LLFS. 
To test for a possible association of LCAD with the immune system, three measures of the 
immune system, including IL-6, white blood cell count, and C-reactive protein, were examined 
in the Long Life Family Study.   Among the Probands, C-reactive protein was increased in 
individuals who were heterozygous or homozygous for the “Q” allele in SNP K333Q (Table 9; 
beta = 0.66±0.22, P = 0.004).  Thus, individuals with the “Q” allele may have increased levels of 
inflammation compared to individuals homozygous for the “K” allele (NIH U.S. National 
Library of Medicine, 2016).  However, this effect was only apparent in the Proband generation, 







Table 9:  Analysis of K333Q (rs2286963) with Measures of Immune Phenotypes in the Long Life Family 
Study 
 Surfactant protein-A in mouse lung tissue and bronchial alveolar lavage fluid. 
Surfactant protein A (SP-A) is a protein important in the proper function of surfactant (Creuwels 
L.A., et al. 1997).  SP-A is additionally involved in the prevention of damage to surfactant 
during lung injury (Khubchandani K.R. and Snyder J.M. 2001).  Additionally, SP-A is involved 
in the immune system through the activation of macrophages, the enhancement of the destruction 
of pathogens in the lung by neutrophils, as well as the suppression of a damaging chronic 
inflammatory response.  SP-A is expressed in ATII where LCAD is expressed in the lung 
(Creuwels L.A., et al. 1997) (Goetzman E.S., et al. 2014).  Therefore, I hypothesized that a lack 
of LCAD would impact the production of SP-A and impact an immune response.  An experiment 
was designed to examine the possible role of LCAD in the immune system by examining the 
amount of SP-A antigen in LCAD -/- mice. The western blot showed inaccurate blotting of the 












Figure 48:  Western Blot of Surfactant Protein-A in 50 µg of Mouse Lung Tissue Lysate 
 
Densitometry with the program, Image J, shows that there is no difference in the dimer 
form of surfactant protein-A antigen (SP-A) (P = 0.41) (Figure 49).  Although, there is 










Figure 49:  Densitometry with Image J of anti-SP-A Western Blot of 50 µg of Second Two Wild Type and 
Four LCAD -/- Mouse Lung Lysate 
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The monomer form is significantly decreased in lung tissue of LCAD KO mice as 
compared to wild type (P = 0.01) (Figure 49).  On the other hand, the monomer form is 
significantly increased in the BALF of LCAD knockout mice as compared to BALF of wildtype 














Figure 50:  Densitometry with Image J of anti-SP-A Western Blot of 50 µg of Second Two Wild Type and 
















Figure 51:  Densitometry with Image J of anti-SP-A Western Blot of 40 µL of Wild Type and LCAD -/- 
Bronchial Alveolar Lavage Fluid 
3.4 CONCLUSIONS 
Acetylation has been shown to have a role in the regulation of recombinant LCAD function.  
Acetylation has been shown to reduce the enzymatic activity of recombinant mouse LCAD at 
lysines K318 and K322 (Bharathi S.S., et al. 2013).  The results of the current study show that 
acetylation also reduces the enzymatic activity of recombinant human LCAD wild type as well 
as recombinant human LCAD with the SNP K333Q (Figure 39).  In addition, this study shows 
that aspirin increases acetylation in hLCAD wild type 30.3 fold (Figure 41).  Aspirin is well 
known to trigger metabolic crises in metabolic disorders, particularly in MCAD as well as 
ACAD9 deficient patients (Green A. and Hall S.M. 1992) (He M., et al. 2007).  Furthermore, 
results of this study showed that acetylation occurs in primary ATII cells where LCAD is 
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expressed (Figure 42).  Therefore, acetylation may be an important regulatory mechanism of 
LCAD in vivo as it has been seen to be here in recombinant protein. 
The consequences of the common polymorphism, K333Q, with regards to human health 
are unknown.  However, my results show that K333Q leads to reduced enzymatic activity with 
the substrates C12-CoA, C14-CoA, C16-CoA, C18-CoA, and C18:1-CoA (Figure 23).  K333Q 
reduces the ability of LCAD to bind substrates or to create the charge-transfer complex with the 
substrates C12-CoA, C16-CoA, and C18-CoA (Figure 26 to 33).  K333Q appears to lead to the loss 
of FAD, which may improve in FAD ratio with the treatment of exogenous FAD (Table 1).  
Reduced enzymatic activity of K333Q can be partially rescued with exogenous FAD.  However, 
recombinant hLCAD K333Q does not reach the level of enzymatic activity seen with hLCAD 
Wt (Figure 37).  K333Q leads to greater instability with a greater percentage of precipitated 
protein at 37 ºC than hLCAD Wt (Figure 15) (Figure 34).  K333Q also reduces LCAD antigen 
by about 80% in the primary ATII cells of individuals, homozygous for the SNP as compared to 
individuals who are homozygous wild type (Figure 44). 
The “Q-allele” of SNP K333Q was shown here to be detrimental to recombinant LCAD 
function.  However, children with different genotypes for SNP K333Q shows no differential 
association with respiratory distress syndrome (Table 3) nor with the outcomes for childhood 
pneumonia (Tables 4 and 5).  On the contrary, the “Q” allele may be beneficial in children 
hospitalized with pneumonia, as children who were homozygous for the wild type “K allele” 
were statistically more likely than expected to be hospitalized with pneumonia (Table 6) (Table 
7).  Although interesting, this analysis needs to be repeated in additional groups.  Furthermore, 
the “Q allele” was associated with increased lung function among spouse controls in the Long 
Life Family Study, but not among other groups (Table 8). 
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One possible explanation for the “Q-allele” of SNP K333Q being beneficial in vivo is that 
LCAD is involved in an immune response.  SP-A is expressed in the ATII cells where LCAD is 
expressed, and is involved in the immune response in the lung (Khubchandani K.R. and Snyder 
J.M. 2001). Western blot of surfactant protein-A in wild-type and LCAD KO mouse lung lysates 
showed significantly decreased antigen of the monomer form of SP-A in the lung tissue of 
LCAD KO mice as compared to wild type (Figure 49).  On the other hand, there is significantly 
increased amount of the antigen of the monomer form of SP-A in the BALF of LCAD KO mice 
as compared to wild type (Figure 51).  Therefore, SP-A appears to be increased in the BALF of 
LCAD KO mice, which does not support an inhibited immune response with the loss of LCAD.  
On the contrary, C-reactive protein as an indication of inflammation was increased in the 
proband group of the Long Life Family Study (Table 9).  This result may be explained by the 
report that a decreased ratio of SP-A to surfactant phospholipid is associated with an increased 
immune response in patients with cystic fibrosis (Khubchandani K.R. and Snyder J.M. 2001).  
The LCAD -/- mice have abnormally structured and reduced surfactant, and also have increased 
SP-A antigen in the BALF (Goetzman E.S., et al. 2014).  Although LCAD -/- mice infected with 
influenza had decreased inflammation.  Therefore, the association found in patients with CF may 
not be equivalent to a deficiency of LCAD. 
 Another possible explanation for the unexpected finding that the “Q-allele” of SNP 
K333Q may improve the catalytic efficiency of LCAD and the lung function of those with the 
SNP is that the variant seems to lead to a loss of the cofactor FAD (Table 1).  However, when 
normalized to FAD content, LCAD K333Q has greater catalytic efficiency (Figure 24).  
Therefore, SNP K333Q may lead to loss of stability and loss of the necessary cofactors LCAD.  
However, before the enzyme loses the cofactors and falls apart, the SNP K333Q increases 
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enzymatic activity with the change of the amino acid to a glutamine leading to a change of 
conformation in the ligand binding sites that increases the enzymatic activity while all parts of 
the enzyme are still in place. 
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4.0  SUMMARY 
In this study, human LCAD and mouse LCAD were observed to have significantly different 
levels of enzymatic activity (Figure 8).  Human LCAD has significantly less enzymatic activity 
than mouse LCAD and a lower catalytic efficiency (Figure 9).  Thus, the human enzyme is not 
biochemically equal to the mouse enzyme and may perhaps perform a different function in 
humans or have an as-yet-undiscovered optimal acyl-CoA substrate.  The tissue expression of 
LCAD also differs between mouse and human tissue lysates (Figure 19).  I have confirmed that 
mouse liver relies heavily upon LCAD for long-chain ACAD activity (Figure 20).  Importantly, I 
report that human hepatocytes express considerable amounts of LCAD, which may explain the 
absence of liver disease in many patients with VLCAD deficiency (Figure 20).  This result also 
suggests that the deleterious polymorphism K333Q needs to be examined in the context of liver 
function amongst VLCADD patients.  
The enzymatic activity of hLCAD K333Q was reduced compared hLCAD Wt (Figure 
23).  On the other hand, the catalytic efficiency of hLCAD K333Q was higher than hLCAD Wt 
(Figure 24).  However, the SNP hLCAD K333Q appears to have a loss of FAD (Table 1).  FAD 
is bound between the monomers of LCAD to form the tetramer.  Similar to what is reported for 
isovaleryl-CoA dehydrogenase (IVD), amino acids from two subunits of the LCAD 
homotetramer bind to the same FAD cofactor (Mohsen A.-W. and Vockley J. 2015).  
Additionally, analysis of the crystal structure of human LCAD revealed that two amino acids 
88 
from a third subunit of the homotetramer, Q328 and H332 bind to FAD (Figure 18).  Therefore, 
each cofactor of FAD is bound by three subunits of the homotetramer of human LCAD.  
Consequently, the loss of FAD could contribute to the decreased stability seen in hLCAD 
K333Q (Figure 15) (Figure 34) through the loss of the connections of the monomers and the 
destabilization of the tetramer.  Interestingly, when the loss of FAD is accounted for by 
normalizing kinetic parameters to FAD content, the mutant K333Q enzyme is more catalytically 
efficient than its wild type counterpart (Figure 24).  But, any kinetic advantage would be 
outweighed by the loss of protein as was observed in western-blotting experiments of primary 
ATII cells from those homozygous for SNP K333Q (Figure 43).  Finally, small amounts of 
ACAD9 and VLCAD antigen were seen in human ATII cell lysates (Figure 43).  This result 
requires further investigation, as their presence may compensate for lost LCAD function in the 
lung and prevent development of an atypical lung phenotype.   
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APPENDIX:  SPECTRA OF STABILITY ASSAY OF RECOMBINANT ENZYME 
The spectra of recombinant enzymes mLCAD, hLCAD Wt, and finally hLCAD K333Q which 
has a glutamine replacing the wild type lysine in all monomers of the pure protein were obtained 
every 0.5 hours for 2 hours and at 19 hours after incubation on ice, at room temperature, at 37 










Figure 52:  Spectra of the Absorbance from 248 nm to 500 nm of Mouse LCAD Incubated A) On Ice, B) 














Figure 53:  Spectra of the Absorbance from 245nm to 500nm of Human LCAD Wild Type Incubated A) On 











Figure 54:  Spectra of the Absorbance from 245nm to 500nm of Human LCAD K333Q Incubated A) On Ice, 
B) Room Temperature, C) 37°C, D) 55°C for 19 Hours 
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